<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Psychiatry</journal-id>
<journal-id journal-id-type="publisher-id">Front. Psychiatry</journal-id>
<journal-title-group>
<journal-title>Frontiers in Psychiatry</journal-title>
</journal-title-group>
<issn pub-type="epub">1664-0640</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28243210</article-id>
<article-id pub-id-type="pmc">5303716</article-id>
<article-id pub-id-type="doi">10.3389/fpsyt.2017.00020</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Psychiatry</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>The Obesity–Impulsivity Axis: Potential Metabolic Interventions in Chronic Psychiatric Patients</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Sfera</surname>
<given-names>Adonis</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
<uri xlink:href="http://frontiersin.org/people/u/54993" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Osorio</surname>
<given-names>Carolina</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="http://frontiersin.org/people/u/160434" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Inderias</surname>
<given-names>Luzmin Acosta</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="http://frontiersin.org/people/u/345761" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Parker</surname>
<given-names>Victoria</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Price</surname>
<given-names>Amy I.</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<uri xlink:href="http://frontiersin.org/people/u/169256" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cummings</surname>
<given-names>Michael</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Patton State Hospital, Psychiatry</institution>, <addr-line>Patton, CA</addr-line>, <country>USA</country></aff>
<aff id="aff2"><sup>2</sup><institution>Loma Linda University, Psychiatry</institution>, <addr-line>Loma Linda, CA</addr-line>, <country>USA</country></aff>
<aff id="aff3"><sup>3</sup><institution>Patton State Hospital, Medicine</institution>, <addr-line>Patton, CA</addr-line>, <country>USA</country></aff>
<aff id="aff4"><sup>4</sup><institution>Patton State Hospital, Dietary</institution>, <addr-line>Patton, CA</addr-line>, <country>USA</country></aff>
<aff id="aff5"><sup>5</sup><institution>Oxford University, Evidence Based Medicine</institution>, <addr-line>Oxford</addr-line>, <country>UK</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Stefan Borgwardt, University of Basel, Switzerland</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Stefania Schiavone, University of Foggia, Italy; Roberto Gradini, Sapienza University of Rome, Italy; Nina Schweinfurth, University of Basel, Switzerland</p>
</fn>
<corresp content-type="corresp" id="cor1">*Correspondence: Adonis Sfera, <email>dr.sfera@gmail.com</email></corresp>
<fn fn-type="other" id="fn002">
<p>Specialty section: This article was submitted to Molecular Psychiatry, a section of the journal Frontiers in Psychiatry</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>13</day>
<month>2</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>8</volume>
<elocation-id>20</elocation-id>
<history>
<date date-type="received">
<day>24</day>
<month>12</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>25</day>
<month>1</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2017 Sfera, Osorio, Inderias, Parker, Price and Cummings.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>Sfera, Osorio, Inderias, Parker, Price and Cummings</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Pathological impulsivity is encountered in a broad range of psychiatric conditions and is thought to be a risk factor for aggression directed against oneself or others. Recently, a strong association was found between impulsivity and obesity which may explain the high prevalence of metabolic disorders in individuals with mental illness even in the absence of exposure to psychotropic drugs. As the overlapping neurobiology of impulsivity and obesity is being unraveled, the question asked louder and louder is whether they should be treated concomitantly. The treatment of obesity and metabolic dysregulations in chronic psychiatric patients is currently underutilized and often initiated late, making correction more difficult to achieve. Addressing obesity and metabolic dysfunction in a preventive manner may not only lower morbidity and mortality but also the excessive impulsivity, decreasing the risk for aggression. In this review, we take a look beyond psychopharmacological interventions and discuss dietary and physical therapy approaches.</p>
</abstract>
<kwd-group>
<kwd>monoamines</kwd>
<kwd>acetylcholine</kwd>
<kwd>short-chain fatty acids</kwd>
<kwd>impulsivity</kwd>
<kwd>microbiome</kwd>
</kwd-group>
<counts>
<fig-count count="3"></fig-count>
<table-count count="3"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="210"></ref-count>
<page-count count="14"></page-count>
<word-count count="11813"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="introduction">
<title>Introduction</title>
<p>Although the prevalence of obesity and metabolic syndrome has been increasing worldwide over the past decades, it is significantly higher in mentally ill patients regardless of exposure to psychotropic drugs (PTDs) (<xref ref-type="bibr" rid="B1">1</xref>–<xref ref-type="bibr" rid="B9">9</xref>). In this regard, it was hypothesized by others that the parallel growth of psychiatric and metabolic disorders may indicate a shared pathoetiology (<xref ref-type="bibr" rid="B10">10</xref>–<xref ref-type="bibr" rid="B13">13</xref>).</p>
<p>Pathological impulsivity encompasses a heterogenous group of psychiatric disorders characterized by inability to resist impulses for engaging in behaviors harmful to self or others. It is encountered in numerous psychiatric conditions, ranging from intermittent explosive disorder, pathological gambling, kleptomania, trichotillomania, and pyromania on the one hand, to schizophrenia, mania, attention-deficit hyperactivity disorder (ADHD), antisocial personality disorder, and drug addictions on the other. The psychopharmacological treatment of these disorders is dependent on the primary pathology and may include almost all classes of PTDs: serotonin reuptake inhibitors, stimulants, antipsychotics, mood stabilizers, and in some instances opioid antagonists.</p>
<p>This observation is in line with the epidemiological studies, linking pathological impulsivity with weight gain and dysmetabolism (<xref ref-type="bibr" rid="B14">14</xref>–<xref ref-type="bibr" rid="B19">19</xref>). There is a growing body of evidence that includes studies in young individuals, indicating that obese/overweight adolescents are more likely to engage in risky behaviors (<xref ref-type="bibr" rid="B20">20</xref>). Along the same lines, nutritional studies reveal that perinatal exposure to high fat diets is more likely to bring about impulsive offspring (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>). Other research in nutrition connected a high trans-fat diet with aggression, while sociological studies pointed to a correlation between antisocial behavior and obesity (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>). Neuroimaging studies shed additional light on the impulsivity–obesity connection as functional magnetic resonance imaging and diffusion tensor imaging studies documented lower perfusion in the orbitofrontal, medial/ventrolateral prefrontal cortex, and middle/superior frontal gyri in impulsive and obese individuals (<xref ref-type="bibr" rid="B25">25</xref>–<xref ref-type="bibr" rid="B28">28</xref>). In addition, this body of evidence includes novel endocrinology studies demonstrating dysregulation of metabolic hormones ghrelin, leptin, and adiponectin in conditions associated with pathological impulsivity, including ADHD, aggression, and antisocial personality disorder (<xref ref-type="bibr" rid="B29">29</xref>–<xref ref-type="bibr" rid="B34">34</xref>). On the other hand, clozapine, an established anti-impulsivity drug, was found to directly alter the expression of leptin and adiponectin genes (<xref ref-type="bibr" rid="B35">35</xref>–<xref ref-type="bibr" rid="B37">37</xref>). Lithium, another anti-impulsivity drug, was found beneficial in correcting the glycemic parameters in diabetes mellitus type 2 (T2DM) by inhibiting glycogen synthase kinase-3 (GSK-3) a leptin-lowering enzyme (<xref ref-type="bibr" rid="B38">38</xref>–<xref ref-type="bibr" rid="B40">40</xref>). As mentioned earlier, lower leptin levels were associated with excessive impulsivity and dyslipidemias (<xref ref-type="bibr" rid="B41">41</xref>).</p>
<p>Multiple psychiatric studies over the past decades established that acetylcholine (ACh) and monoamines (MAs) including norepinephrine, dopamine, histamine, and serotonin are involved in a wide range of psychiatric disorders, including those marked by pathological impulsivity (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B42">42</xref>–<xref ref-type="bibr" rid="B44">44</xref>). As these neurotransmitters were demonstrated to also modulate the hypothalamic feeding centers, it should not come as a surprise that impulsivity and obesity are intertwined (<xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B46">46</xref>). Indeed, most antiobesity drugs present with agonistic action at the receptors in which many PTDs antagonize, suggesting the possibility of a psychometabolic continuum (<xref ref-type="bibr" rid="B46">46</xref>).</p>
<p>The development of PTDs with fewer metabolic adverse effects currently represents a major unmet need in psychiatry. As obesity and metabolic dysfunction in psychiatric patients trigger higher morbidity and mortality rates than in the general population, there is a heightened urgency for their prevention and early correction. Therefore, until this need is met, optimal utilization of available pharmacological and non-pharmacological tools is crucial for the overall well-being of these patients.</p>
<p>At present, the treatment of metabolic disorders in psychiatric patients is not only underutilized but also frequently delayed, rendering correction more difficult to achieve (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>). Indeed, after the diagnosis of obesity or metabolic syndrome is established, there are few effective interventions for reversing these conditions. In general, these interventions revolve around replacing an orexigenic with a less orexigenic drug, at the risk of clinical destabilization, or lifestyle and behavioral changes that have proved difficult to implement in this population (<xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B48">48</xref>). Therefore, clinicians should adopt preemptive approaches, striving to avoid or delay the onset of obesity, and the metabolic syndrome instead of correcting them <italic>post hoc</italic> (<xref ref-type="bibr" rid="B7">7</xref>).</p>
<p>More studies are needed to assess the efficacy of preventive metabolic interventions, including the utilization of available antiobesity drugs in psychiatric disorders and PTD-induced obesity. There are even fewer studies on alternative modalities, including nutrition, physical therapy, and parasympathetic stimulation <italic>via</italic> cholinesterase inhibitors or transcutaneous auricular vagal nerve stimulation (taVNS).</p>
<p>In this article, we will review some of these modalities after a brief discussion on antiobesity drugs and their action in the hypothalamic feeding centers.</p>
</sec>
<sec id="S2">
<title>Arcuate (ARC) Nucleus: Where Psychopharmacology and Antiobesity Pharmacopeias Collide</title>
<p>Hunger, satiety, and energy homeostasis are controlled by the neuronal networks in the mediobasal hypothalamus and some brainstem areas. The ARC nucleus of the hypothalamus contains the first order neurons that balance hunger and satiety in order to maintain a stable body weight (<xref ref-type="bibr" rid="B49">49</xref>). This balancing act requires a constant cross-talk between the ARC nucleus and the peripheral organs, which takes place <italic>via</italic> metabolic hormones, neural input, and neurotransmitters, including MA and ACh (<xref ref-type="bibr" rid="B50">50</xref>).</p>
<p>The anorexigenic system that lowers appetite is composed of proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART) neurons. They produce the alpha-melanocyte stimulating hormone (alpha-MSH) that binds to the melanocortin 3 and 4 receptors (MC3Rs and MC4Rs) expressed by the second order neurons located in the periventricular nucleus and the lateral hypothalamic area (LHA) (<xref ref-type="bibr" rid="B51">51</xref>) (Figure <xref ref-type="fig" rid="F1">1</xref>).</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p><bold>The anorexigenic system: alpha-melanocyte stimulating hormone (alpha-MSH) activates MC3/4 receptors expressed on second order neurons, inhibiting appetite</bold>. The orexigenic system: agouti-related protein (AgRP) is a competitor of alpha-MSH at MC3/4 receptors, augmenting appetite. Adiponectin, leptin, ghrelin, and serotonin activate the anorexigenic system. The action of these hormones on the orexigenic system results in the release of the inhibitory neurotransmitter GABA, which applies the brake on the anorexigenic system, increasing appetite. Abbreviations: AdipoR, adiponectin receptors; nAChRs, nicotinic cholinergic receptors; LepRs, leptin receptors; GHS-R1a, ghrelin receptors; serotonin 5-HT2C and 5-HT1A receptors.</p>
</caption>
<graphic xlink:href="fpsyt-08-00020-g001"></graphic>
</fig>
<p>The orexigenic system, which increases the appetite, consists of neuropeptide Y (NPY) and agouti-related protein (AgRP). They produce NPY, GABA, and the AgRP. AgRP is an antagonist of alpha-MSH at MC3Rs and MC4Rs prevents their activation, whereas GABA inhibits the POMC/CART neurons. Both of these actions result in appetite augmentation.</p>
<p>In addition to these neuronal groups, ARC also contains dopamine neurons which project to the anterior pituitary gland where they inhibit prolactin secretion (Figure <xref ref-type="fig" rid="F1">1</xref>). Blocking dopamine-2 (D-2) receptors by PTDs often results in hyperprolactinemia, a common adverse effect of high potency antipsychotic drugs (<xref ref-type="bibr" rid="B52">52</xref>).</p>
<p>Over the past few years, new drugs indicated for the long-term treatment of obesity obtained FDA approval. Interestingly, two of them are combinations of PTDs utilized in the treatment of psychiatric disorders. For example, phentermine–topiramate extended release (Qsymia) and naltrexone–bupropion extended release (Contrave) have been prescribed individually in affective disorders and drug addictions. These drugs may have a place in the preventive treatment of PTD-induced obesity as they may be prescribed “off label” in select patients needing more adequate mood stabilization. In this regard, four large randomized, double-blind, placebo controlled trials support the preventive use of topiramate alone for PTD-induced weight gain (<xref ref-type="bibr" rid="B53">53</xref>). Concomitant utilization of topiramate with orexigenic PTDs may constitute a preemptive intervention to avoid or delay the onset of obesity and metabolic dysregulation (Table <xref ref-type="table" rid="T1">1</xref>). About 10% of patients may experience mild to moderate cognitive adverse effects early on topiramate treatment with verbal fluency being more affected compared to other antiepileptic drugs.</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p><bold>Antiobesity and anti-diabetes mellitus type 2 (T2DM) drugs for potential use in psychiatry</bold>.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">Combination drugs</th>
<th align="left" colspan="1" rowspan="1" valign="top">FDA approved for</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Phentermine/topiramate extended release (QSYMIA)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Obesity long term</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Bupropion/naltrexone extended release (CONTRAVE)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Obesity long term</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Glucagon-like peptide-1 agonists</bold>
</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Liraglutide (Victoza)</td>
<td align="left" colspan="1" rowspan="1" valign="top">T2DM + obesity long term</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Exenatide (Byetta)</td>
<td align="left" colspan="1" rowspan="1" valign="top">T2DM (possible antiobesity action)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Albiglutide (Tanzeum)</td>
<td align="left" colspan="1" rowspan="1" valign="top">T2DM (possible antiobesity action)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Monoamine agonists</bold>
</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Phentermine, diethylpropion, benzphetamine</td>
<td align="left" colspan="1" rowspan="1" valign="top">Obesity (short term)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Bromocriptine (Cycloset)</td>
<td align="left" colspan="1" rowspan="1" valign="top">T2DM (possible antiobesity action)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Amantadine (Symmetrel)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Influenza A, Parkinson’s disease (possible antiobesity action)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Locaserin</td>
<td align="left" colspan="1" rowspan="1" valign="top">Antiobesity long term</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Cholinergic agonists and enhancers</bold>
</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Sofinicline</td>
<td align="left" colspan="1" rowspan="1" valign="top">(Developmental stage-antiobesity)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Donepezil, rivastigmine, galantamine</td>
<td align="left" colspan="1" rowspan="1" valign="top">Alzheimer’s diseases (possible antiobesity and anti T2DM action)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Histamine agonists</bold>
</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Betahistine</td>
<td align="left" colspan="1" rowspan="1" valign="top">Meniere’s disease (possible antiobesity and anti T2DM action)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Melanin-concentrating hormone antagonists</td>
<td align="left" colspan="1" rowspan="1" valign="top">(Developmental stage-antiobesity)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>In parenthesis: non-FDA approved</italic>.</p>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="S3">
<title>Metformin</title>
<p>Metformin is a drug widely prescribed in psychiatric patients diagnosed with T2DM, but rarely in a preventive manner, even though several studies found this drug to be efficient in preventing both obesity and T2DM (<xref ref-type="bibr" rid="B54">54</xref>–<xref ref-type="bibr" rid="B56">56</xref>). Since metformin is known for its relatively benign adverse effects, it could be prescribed from the treatment onset along with the orexigenic PTDs.</p>
<p>Metformin was demonstrated to result in 2.93–5 kg weight loss after 6 months of treatment even when prescribed after the onset of metabolic dysregulation (<xref ref-type="bibr" rid="B55">55</xref>). More studies are needed to assess the benefits of preventive metformin use alone or in combination with other antiobesity agents.</p>
</sec>
<sec id="S4">
<title>Glucagon-Like Peptide-1 (GLP-1)</title>
<p>Recently, there has been a strong interest in the GLP-1 agonists, including liraglutide (Victoza), exenatide (Byetta), and albiglutide (Tanzeum). These agents have been shown effective in halting weight gain in diabetic patients and their antiobesity action is most likely mediated <italic>via</italic> GLP-1 receptors expressed on POMC/CART neurons (<xref ref-type="bibr" rid="B57">57</xref>) (Figure <xref ref-type="fig" rid="F1">1</xref>).</p>
<p>In addition, novel studies demonstrate that GLP-1 inhibition may mediate clozapine-induced weight gain and metabolic dysregulation, suggesting that GLP-1 agonists could reverse both (<xref ref-type="bibr" rid="B58">58</xref>). To the best of our knowledge, currently, there is one ongoing study aiming at exploring liraglutide’s effects on glucose tolerance in patients on clozapine or olanzapine treatment (<xref ref-type="bibr" rid="B59">59</xref>). The once-a-week drug exenatide did not promote weight loss in this population (<xref ref-type="bibr" rid="B60">60</xref>). As liraglutide was demonstrated to be more effective than the GLP-1 mimetics, a clinical trial should be initiated to assess the efficacy of this drug for PTD-induced obesity either alone or in combination with another compound, such as locaserin (<xref ref-type="bibr" rid="B61">61</xref>). The once-a-week albiglutide was also not tested for weight loss in PTD-induced obesity. A large study found this drug effective, especially as an adjunct to metformin, suggesting that it could be helpful for psychiatric patients with inadequate glycemic control on metformin alone (<xref ref-type="bibr" rid="B62">62</xref>). In addition, since liraglutide has both T2DM and weight loss indication, it could be prescribed more often in overweight/obese psychiatric patients, especially when other agents cannot achieve adequate glycemic stabilization. Interestingly, novel studies demonstrate that GLP-1 agonists may have PTD-synergistic actions on impulsivity, suggesting that liraglutide-treated psychiatric patients may be managed with lower PTDs doses (<xref ref-type="bibr" rid="B63">63</xref>–<xref ref-type="bibr" rid="B67">67</xref>). Furthermore, since GLP-1 signaling was suggested as a common pathophysiological mechanism in both Alzheimer’s disease and T2DM, GLP-1 agonists may prevent cognitive decline (<xref ref-type="bibr" rid="B68">68</xref>).</p>
</sec>
<sec id="S5">
<title>Locaserin</title>
<p>The novel antiobesity drug, locaserin, is an agonist at serotonin 5-HT2C receptors that are antagonized by some PTDs, inducing the adverse effect of weight gain. Interestingly, preclinical studies demonstrated the efficacy 5-HT2C agonists for the treatment of excessive impulsivity (<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B69">69</xref>–<xref ref-type="bibr" rid="B71">71</xref>).</p>
<p>Different studies point to a connection between serotonin signaling and the metabolic hormones—ghrelin, leptin, and adiponectin—which were also linked to impulsivity (<xref ref-type="bibr" rid="B29">29</xref>–<xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B41">41</xref>). For example, studies in rodents show that leptin modulates the biosynthesis and release of serotonin by the raphe nuclei (<xref ref-type="bibr" rid="B72">72</xref>–<xref ref-type="bibr" rid="B74">74</xref>). Other studies report that leptin receptors (LepRs) act synergistically with 5-HT2C expressed on POMC/CART neurons and with 5-HT1B receptors on NPY/AgRP neurons (<xref ref-type="bibr" rid="B75">75</xref>) (Figure <xref ref-type="fig" rid="F1">1</xref>). Clozapine, a drug with known anti-impulsivity actions and orexigenic adverse effects, is an antagonist at both 5-HT2C and 5-HT1B receptors. In addition, as mentioned earlier, clozapine alters the expression of leptin and adiponectin genes, suggesting direct effects on both impulsivity and weight gain.</p>
<p>To the best of our knowledge, locaserin has not been tested in PTD-induced weight gain, but its receptor profile suggests it may be beneficial as an adjunct in clozapine-, olanzapine-, or mirtazapine-treated patients.</p>
<p>A body of literature links the reduced serotonergic 5-HT1B receptor activity with impulsivity and drug addictions (<xref ref-type="bibr" rid="B76">76</xref>–<xref ref-type="bibr" rid="B79">79</xref>). In the hypothalamus, the 5-HT1B receptors are expressed by the NPY/AgRP neurons and their activation inhibits the release of GABA, thus disinhibiting the anorexigenic system, inducing appetite suppression (Figure <xref ref-type="fig" rid="F1">1</xref>). The 5-HT1B receptors were demonstrated to act synergistically in appetite suppression with the 5HT2C at POMC/CART receptors (<xref ref-type="bibr" rid="B75">75</xref>). At present, there are no concomitant agonists at 5-HT2C and 5-HT1B receptors, but such drugs may be expected to present with superior antiobesity and anti-impulsivity actions. As discussed above, lithium, a major anti-impulsivity drug, inhibits GSK-3, a 5-HT1B-blocking enzyme. Over-expressed GSK-3 was associated with excessive impulsivity in multiple psychiatric syndromes, including mania, suicide, and schizophrenia (<xref ref-type="bibr" rid="B80">80</xref>–<xref ref-type="bibr" rid="B84">84</xref>). In addition, GSK-3 upregulation was demonstrated in obesity and insulin resistance (<xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B85">85</xref>, <xref ref-type="bibr" rid="B86">86</xref>). Since lithium was documented to possess anti-diabetic properties, GSK-3 inhibitors are currently T2DM targets (<xref ref-type="bibr" rid="B40">40</xref>). Indeed, three decades ago, it was noted that lithium acted synergistically with some antidiabetic drugs; however, the mechanism was unknown at that time (<xref ref-type="bibr" rid="B87">87</xref>–<xref ref-type="bibr" rid="B89">89</xref>) (Table <xref ref-type="table" rid="T1">1</xref>).</p>
</sec>
<sec id="S6">
<title>Dopaminergic Drugs in Obesity–Impulsivity Axis</title>
<p>Some of the FDA approved antiobesity agents are agonists at dopamine D-2 receptors that are antagonized by all clinically utilized antipsychotic drugs (<xref ref-type="bibr" rid="B90">90</xref>). The antiobesity D-2 agonists include phentermine, diethylpropion, benzphetamine, and bupropion (as part of the combination drug Contrave). In addition, the D-2 stimulants bromocriptine and amantadine have been associated with weight loss (<xref ref-type="bibr" rid="B91">91</xref>, <xref ref-type="bibr" rid="B92">92</xref>). For example, amantadine has demonstrated efficacy in overweight/obese patients treated with olanzapine (<xref ref-type="bibr" rid="B91">91</xref>). Bromocriptine under the market name Cycloset recently obtained FDA indication for the treatment of T2DM. This drug has been underutilized in PTD-associated glycemic dysfunction, although it may be beneficial for diabetic patients requiring treatment with risperidone, paliperidone, or some antidepressants that are often associated with hyperprolactinemia.</p>
<p>Recent studies revealed that elevated prolactin induces pancreatic beta cells to secrete insulin. Chronic hyperprolactinemia induces hyperinsulinemia, eventually resulting in beta cells exhaustion and T2DM (Figure <xref ref-type="fig" rid="F2">2</xref>). Aside from the anterior pituitary, prolactin is also released by the adipose tissue as a pro-inflammatory cytokine demonstrated to augment the metabolic inflammation associated with obesity (<xref ref-type="bibr" rid="B93">93</xref>, <xref ref-type="bibr" rid="B94">94</xref>). This is one of the primary reasons clinicians should address hyperprolactinemia promptly in PTD-treated patients, after prolactinomas have been ruled out (<xref ref-type="bibr" rid="B94">94</xref>). Novel studies do not support the older concept that bromocriptine or other D-2 stimulants invariably precipitate psychosis. Persistently elevated prolactin was demonstrated by large studies to increase the all-cause mortality, emphasizing the need for treating this condition promptly (<xref ref-type="bibr" rid="B95">95</xref>, <xref ref-type="bibr" rid="B96">96</xref>). In addition, other studies demonstrated the benefit of D-2 stimulation in patients with negative symptoms of schizophrenia (<xref ref-type="bibr" rid="B97">97</xref>, <xref ref-type="bibr" rid="B98">98</xref>). Furthermore, some researchers hypothesized that hyperprolactinemia may exacerbate both schizophrenia and T2DM (<xref ref-type="bibr" rid="B99">99</xref>).</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p><bold>Prolactin receptors (PRLR), muscarinic-3 cholinergic, and glucagon-like peptide-1 (GLP-1) receptors are expressed on pancreatic beta-cells, facilitating insulin release along with serotonin and dopamine</bold>.</p>
</caption>
<graphic xlink:href="fpsyt-08-00020-g002"></graphic>
</fig>
<p>Appetite contains a large hedonic component mediated by the central reward system. A striatal hypodopaminergic state is believed to trigger overnutrition, which in turn augments dopamine transmission. According to this model, D-2 stimulants correct the hypodopaminergia, lowering the overnutrition reward (<xref ref-type="bibr" rid="B100">100</xref>–<xref ref-type="bibr" rid="B102">102</xref>). Indeed, reduced D-2 receptor density was demonstrated in obese individuals, implying impaired dopaminergic signaling in this metabolic disorder (<xref ref-type="bibr" rid="B103">103</xref>). Psychiatric patients treated with antipsychotic drugs (D-2 blockers) may present with an enduring iatrogenic hypodopaminergic state, which in turn triggers overnutrition to augment dopamine levels.</p>
<p>Amantadine, bromocriptine, or phentermine–topiramate extended release should be encouraged in psychiatric patients, especially when presenting with extrapyramidal symptoms or elevated prolactin.</p>
<p>Lisdexamfetamine, a dopaminergic pro-drug metabolized to dexamphetamine, was approved by the FDA for ADHD; however, its appetite suppressant activity and low abuse potential may render it useful in PTD-induced obesity. Recently, the effectiveness of this compound was demonstrated in binge eating (<xref ref-type="bibr" rid="B104">104</xref>). In addition, its stimulant action was associated with significant improvements in negative symptoms of schizophrenia without worsening the positive symptoms (<xref ref-type="bibr" rid="B105">105</xref>).</p>
</sec>
<sec id="S7">
<title>Acetylcholine</title>
<p>A novel line of research demonstrates that ACh signaling and metabolic pathways intersect, both in the pancreas and the hypothalamus (<xref ref-type="bibr" rid="B106">106</xref>, <xref ref-type="bibr" rid="B107">107</xref>). Centrally, nicotine activates the nicotinic cholinergic receptors (nAChRs) expressed on POMC/CART neurons, turning the anorexigenic system “on” and lowering appetite (Figure <xref ref-type="fig" rid="F1">1</xref>). This was demonstrated to take place in smokers, while following smoking cessation, the lack of anorexigenic activation heightens the appetite, lading to weight gain. In addition, as nAChRs are also expressed on the second order neurons in the LHA and the perifornical organ. Smoking discontinuation affects these areas also, inducing weight gain (<xref ref-type="bibr" rid="B108">108</xref>).</p>
<p>Peripherally, ACh enables insulin release (in response to glucose) from the pancreatic beta cells <italic>via</italic> muscarinic-3 (M-3) receptors. Pancreatic alpha cells secrete ACh, facilitating the release of insulin from the beta cells (<xref ref-type="bibr" rid="B109">109</xref>, <xref ref-type="bibr" rid="B110">110</xref>) (Figure <xref ref-type="fig" rid="F2">2</xref>).</p>
<p>As several PTDs are known to block the M-3 receptors, they may induce glycemic dysregulation (<xref ref-type="bibr" rid="B111">111</xref>). Interestingly, insulin is synthesized and released from the beta cells along with serotonin and dopamine molecules, demonstrating once more the interconnectedness between energy metabolism and ACh/MAs. This finding is in line with the epidemiological studies associating smoking cessation with increased risk for T2DM for up to 12 years (<xref ref-type="bibr" rid="B112">112</xref>).</p>
<p>In light of these data, it should not come as a surprise that obesity and T2DM have been associated with the over-expression of Ach-degrading enzymes—butyrylcholinesterase (BChE) and acetylcholinesterase (AChE)—which tone down cholinergic signaling. Indeed, cholinesterase inhibitors—donepezil, rivastigmine, and galantamine—were found beneficial in metabolic syndrome by some researchers (<xref ref-type="bibr" rid="B113">113</xref>–<xref ref-type="bibr" rid="B115">115</xref>). In addition, these drugs are currently utilized in patients with Alzheimer’s disease for the treatment of aggression, suggesting a psychometabolic role (<xref ref-type="bibr" rid="B116">116</xref>). Preventive use of these agents in psychiatric patients could preempt the development of metabolic dysfunction and obesity. Rivastigmine that inhibits both AChE and BChE was found to be a more effective anti-impulsivity agent in dementias (<xref ref-type="bibr" rid="B117">117</xref>). Interestingly, BChE was demonstrated to hydrolyze both ACh and ghrelin, thus comprising an antiobesity/impulsivity target (<xref ref-type="bibr" rid="B114">114</xref>, <xref ref-type="bibr" rid="B118">118</xref>, <xref ref-type="bibr" rid="B119">119</xref>). Moreover, LepRs were demonstrated to act synergistically with both serotonin and ACh receptors on POMC/CART neurons, indicating a close coordination between the metabolic hormones and these neurotransmitters (<xref ref-type="bibr" rid="B75">75</xref>). Furthermore, the existence of a leptin–dopamine axis was implied by preclinical studies which found that mesolimbic leptin signaling modulates the CNS reward system (<xref ref-type="bibr" rid="B120">120</xref>).</p>
<p>Melatonin and serotonin 5-HT2C receptors were demonstrated to be coexpressed in various areas of the CNS, possibly including POMC/CART neurons, explaining the frequently discussed antiobesity effect of melatonin (<xref ref-type="bibr" rid="B121">121</xref>).</p>
<p>The impaired expression of CHRNA gene, coding for the nicotinic acetylcholine receptors, has been associated with disorders marked by excessive impulsivity, including ADHD, drug addictions, and antisocial personality disorder (<xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B122">122</xref>, <xref ref-type="bibr" rid="B123">123</xref>). Sofinicline, a novel nicotinic agonist believed to augment CHRNA expression, is currently being tested for ADHD but appears promising in metabolic syndrome, T2DM, and eating disorders (<xref ref-type="bibr" rid="B124">124</xref>–<xref ref-type="bibr" rid="B126">126</xref>). The metabolic action of sofinicline is probably due to ghrelin modulation of POMC/CART neurons <italic>via</italic> nicotinic receptors coexpressed with 5-HT2C (<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B127">127</xref>). This recently revealed receptor–receptor interaction may lead to the development of novel compounds for metabolic syndrome and impulsivity (<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B128">128</xref>–<xref ref-type="bibr" rid="B130">130</xref>).</p>
<p>Clinicians should be encouraged to prescribe cholinesterase inhibitors in a preventive manner in psychiatric patients susceptible to PTD-induced obesity and dysmetabolism, especially in the presence of schizophrenia or dementia-related cognitive impairments. In this respect, rivastigmine patch represents a low risk intervention with several advantages over oral medications. Moreover, since impaired cholinergic signaling was involved in both metabolic and impulsivity disorders, clinicians should avoid the use of anticholinergic drugs even in younger patients and consider replacing them with amantadine for the extrapyramidal adverse effects of antipsychotic drugs and with melatonin or ramelteon for insomnia. Furthermore, cholinergic signaling may be enhanced <italic>via</italic> taVNS, which represents another low risk intervention for improving insulin sensitivity (<xref ref-type="bibr" rid="B131">131</xref>). Interestingly, taVNS has documented efficacy in depression, which may represent an additional benefit for psychiatric patients (<xref ref-type="bibr" rid="B132">132</xref>).</p>
</sec>
<sec id="S8">
<title>Histamine</title>
<p>The relationship between histamine and metabolism was first described in the 1950s, yet the development of histaminergic treatments for metabolic disorders and obesity is still in its infancy (<xref ref-type="bibr" rid="B133">133</xref>). The blockade of histamine-1 (H-1) receptors by PTDs was associated with both obesity and T2DM, suggesting the involvement of histaminergic pathways in energy homeostasis (<xref ref-type="bibr" rid="B131">131</xref>, <xref ref-type="bibr" rid="B134">134</xref>–<xref ref-type="bibr" rid="B136">136</xref>). Briefly, H-1 and H-2 receptors’ blockade induces sedation, while antagonism at H-3 receptors results in wakefulness, as H-3 receptors are primarily autoreceptors.</p>
<p>Some clinical and preclinical studies demonstrated that betahistine, a centrally acting H-1 agonist and partial H-3 antagonist, was effective as an antiobesity drug, especially in younger women (<xref ref-type="bibr" rid="B137">137</xref>). Studies with olanzapine-induced obesity in rodents also demonstrated weight loss after exposure to betahistine (<xref ref-type="bibr" rid="B138">138</xref>). However, as other studies failed to establish a direct link between histamine and body weight, an indirect action is now suspected <italic>via</italic> other neurotransmitter systems or metabolic hormones, including thyrotropin-releasing hormone, growth hormone, and leptin (<xref ref-type="bibr" rid="B139">139</xref>–<xref ref-type="bibr" rid="B141">141</xref>). Indeed, novel human studies report that H-1 receptor antagonists inhibit alpha 7nAChRs which turn “off” the POMC/CART anorexigenic system (<xref ref-type="bibr" rid="B139">139</xref>). As alpha 7nAChRs are involved in cognition, histamine-blocking agents (including some PTDs) may represent both metabolic and cognitive risk factors.</p>
<p>Aside from these indirect actions on feeding, histamine was recently demonstrated to directly control the orexigenic melanin-concentrating hormone (MCH) (<xref ref-type="bibr" rid="B142">142</xref>). Indeed, the MCH receptor antagonists are currently thought of as promising antiobesity agents (<xref ref-type="bibr" rid="B143">143</xref>). As MCH neurons express H-3, but not H-1 or H-2 receptors, it is likely that histamine inhibits MCH secretion <italic>via</italic> H-3 receptors. Several studies indicate that histamine also exerts H-3-mediated anti-diabetic properties (<xref ref-type="bibr" rid="B144">144</xref>–<xref ref-type="bibr" rid="B146">146</xref>) (Table <xref ref-type="table" rid="T1">1</xref>).</p>
<p>Furthermore, human microglial cells were documented to express H-3 receptors that are responsible for their activation (<xref ref-type="bibr" rid="B147">147</xref>). As numerous neuropsychiatric conditions were linked to microglial activation, H-3 receptors’ antagonists are currently evaluated for their efficacy in schizophrenia and Alzheimer’s disease (<xref ref-type="bibr" rid="B147">147</xref>, <xref ref-type="bibr" rid="B148">148</xref>). Moreover, novel studies suggest that H-3 blockade may be associated with decreased impulsivity, especially in dementia, Parkinson’s disease, ADHD, and drug addiction (<xref ref-type="bibr" rid="B149">149</xref>–<xref ref-type="bibr" rid="B152">152</xref>). As histamine is known to be modulated by leptin and reduced leptin was associated with impulsivity, these finding are in line with the research connecting histamine with obesity–impulsivity axis (<xref ref-type="bibr" rid="B30">30</xref>–<xref ref-type="bibr" rid="B32">32</xref>).</p>
</sec>
<sec id="S9">
<title>The Brain–Gut Axis: May the Microbes be with You</title>
<p>Dietary interventions have been extremely underutilized in psychiatric patients despite accumulating evidence for their benefits.</p>
<p>The Alternate Healthy Eating Index 2010 (AHEI-2010) is a measure of diet quality. A high AHEI score was documented to lower the risk of chronic disease, including T2DM and cardiovascular disease and to reverse the metabolic syndrome (<xref ref-type="bibr" rid="B153">153</xref>–<xref ref-type="bibr" rid="B155">155</xref>). High AHEI score diets have demonstrated benefits in the affective and cognitive disorders, but they were not studied in schizophrenia or PTD-induced obesity (<xref ref-type="bibr" rid="B156">156</xref>, <xref ref-type="bibr" rid="B157">157</xref>). These diets are thought to exert their beneficial effects by stabilizing the gut microbiome.</p>
<p>The human microbiome consists of over 100 trillion bacteria, fungi, and protozoa which inhabit the gastrointestinal (GI) tract, living in symbiosis with the host cells. Several lines of evidence point to the potential role of gut microbiota in modulating not only the host energy metabolism but also information processing and behavior (<xref ref-type="bibr" rid="B158">158</xref>, <xref ref-type="bibr" rid="B159">159</xref>). Human and animal studies demonstrated that obesity was associated with GI “overpopulation” with phylum Firmicutes and concomitant decreases in phylum Bacteriodetes (<xref ref-type="bibr" rid="B160">160</xref>, <xref ref-type="bibr" rid="B161">161</xref>). Interestingly, administration of an antibiotic along with olanzapine minimized the amount of the weight gain in rodents, a finding that may be in line with the antibiotic minocycline reducing psychotic symptoms in patients with schizophrenia. Minocycline is a tetracycline that was demonstrated to not only modulate the dopaminergic and glutamatergic CNS signaling but also to restore the physiologic Firmicutes/Bacteroidetes ratio in the gut with positive effect on hypertension (<xref ref-type="bibr" rid="B162">162</xref>).</p>
<p>These studies suggest that that gut microbiota may be involved not only in the etiology of obesity but also in schizophrenia, perhaps explaining the predisposition to metabolic disorders encountered in psychiatric patients (<xref ref-type="bibr" rid="B163">163</xref>, <xref ref-type="bibr" rid="B164">164</xref>). In addition, preclinical studies show that transplantation of GI tract microorganisms from the obese into the lean mice was followed by weight gain in the later. Interestingly, fecal analysis of olanzapine treated rodents, demonstrated increases in Firmicutes and decreases in Bacteriodetes phyla, a pattern identical to the one found in obese humans (<xref ref-type="bibr" rid="B165">165</xref>, <xref ref-type="bibr" rid="B166">166</xref>).</p>
<p>Other novel studies linked low dietary fiber with the dysregulation of Firmicutes/Bacteriodetes ratio. The colonic microbiota is known to induce fermentation of dietary fiber, resulting in the production of beneficial short-chain fatty acids (SCFAs), including butyrate and propionate. The SCFAs deficiency is believed to represent a risk factor in the pathogenesis of obesity (<xref ref-type="bibr" rid="B167">167</xref>). In this respect, butyrate was found protective against insulin resistance and inflammation, while propionate was demonstrated to lower cholesterol synthesis (<xref ref-type="bibr" rid="B168">168</xref>). Moreover, SCFAs were shown to augment the production of leptin which, as discussed above, was found to be decreased in disorders marked by impulsivity, thus linking SCFAs with psychiatric conditions (<xref ref-type="bibr" rid="B169">169</xref>).</p>
<p>Short-chain fatty acids were demonstrated not only to reach the bloodstream but also to cross the blood–brain barrier (BBB) and alter the hypothalamic leptin and adiponectin gene expression (<xref ref-type="bibr" rid="B170">170</xref>, <xref ref-type="bibr" rid="B171">171</xref>). Activation of adiponectin receptors, expressed on both POMC/CART and NPY/AgRP are known to potentiate the function of leptin, lowering impulsivity (<xref ref-type="bibr" rid="B172">172</xref>, <xref ref-type="bibr" rid="B173">173</xref>). Interestingly, many patients with schizophrenia treated with second-generation antipsychotic drugs were found to have lower plasma adiponectin and leptin levels (<xref ref-type="bibr" rid="B174">174</xref>, <xref ref-type="bibr" rid="B175">175</xref>). Studies in metabolism indicate that hypoadiponectinemia lowers the skeletal muscle uptake of postprandial glucose (insulin resistance), eventually leading to T2DM (<xref ref-type="bibr" rid="B176">176</xref>, <xref ref-type="bibr" rid="B177">177</xref>). Moreover, supplementation with dietary fiber was demonstrated to increase adiponectin levels by up to 115%, suggesting that SCFAs play a key role in adiponectin biosynthesis (<xref ref-type="bibr" rid="B178">178</xref>).</p>
<p>Western diets in general are known for lacking adequate amounts of dietary fiber. For example, typical Western adults were shown to consume 5–10 g of fiber daily, as opposed to the 35 or 50 g which is considered optimal (<xref ref-type="bibr" rid="B179">179</xref>). Patients with schizophrenia were demonstrated to consume an even lower amount of dietary fiber compared to the overall Western population, perhaps explaining the low adiponectin levels documented in this group (<xref ref-type="bibr" rid="B180">180</xref>). Mediterranean diets and variants aside from their demonstrated anti-inflammatory actions were found to facilitate SCFAs biosynthesis (<xref ref-type="bibr" rid="B181">181</xref>) (Table <xref ref-type="table" rid="T2">2</xref>).</p>
<table-wrap id="T2" position="float">
<label>Table 2</label>
<caption>
<p><bold>Dietary interventions in metabolic syndrome</bold>.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">Dietary intervention</th>
<th align="center" colspan="1" rowspan="1" valign="top">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Adherence to Alternate Healthy Eating Index-2010</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B153">153</xref>, <xref ref-type="bibr" rid="B154">154</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Anti-inflammatory diets</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B154">154</xref>, <xref ref-type="bibr" rid="B157">157</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Adiponectin-increasing diets</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B178">178</xref>, <xref ref-type="bibr" rid="B182">182</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">High dietary fiber modifications</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B183">183</xref>, <xref ref-type="bibr" rid="B184">184</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Dietary polyphenols</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B185">185</xref>, <xref ref-type="bibr" rid="B186">186</xref>)</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Dietary polyphenols were documented to help maintain the adequate gut microbial balance (<xref ref-type="bibr" rid="B187">187</xref>). In addition, polyphenols were shown to be protective against T2DM and possibly psychiatric disorders manifested by impulsivity (<xref ref-type="bibr" rid="B182">182</xref>–<xref ref-type="bibr" rid="B186">186</xref>). To the best of our knowledge, at present, there are no studies on polyphenol/high fiber diets in psychiatric or PTD-treated patients. We suggest a trial with a modified Mediterranean diet, incorporating high dietary fiber, polyphenols, and SCFA. The efficacy of this approach can be monitored not only <italic>via</italic> BMI and the glycemic parameters but also by plasma adiponectin and leptin levels.</p>
</sec>
<sec id="S10">
<title>Skeletal Muscle and the “Exercise Factors”</title>
<p>In addition to enabling the human body mobility, the over 600 skeletal muscles comprise a complex endocrine organ, known for the secretion of a growing number of “myokines” which exert both local and distal effects. “Exercise factors” are a subgroup of myokines released into the circulation during the exercise (<xref ref-type="bibr" rid="B188">188</xref>, <xref ref-type="bibr" rid="B189">189</xref>). Among them, the peroxisome proliferator-activated receptor-γ coactivator 1alpha (PGC-1alpha) is the most studied as it was shown to increase both the skeletal muscle glucose uptake and the oxidation of fatty acids (<xref ref-type="bibr" rid="B190">190</xref>). A sedentary lifestyle with lowered expression of PGC-1alpha is associated with weight gain, inflammation, and decreased insulin secretion, pathological changes that eventually culminate in T2DM and obesity (<xref ref-type="bibr" rid="B191">191</xref>) (Table <xref ref-type="table" rid="T3">3</xref>).</p>
<table-wrap id="T3" position="float">
<label>Table 3</label>
<caption>
<p><bold>Specific therapeutic modalities described in metabolic syndrome</bold>.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">Therapeutic modalities</th>
<th align="center" colspan="1" rowspan="1" valign="top">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Transcutaneous vagus nerve stimulation</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B132">132</xref>, <xref ref-type="bibr" rid="B192">192</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Isometric exercises</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B193">193</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Swiss ball exercises</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B194">194</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Whole body vibration exercises</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B195">195</xref>)</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Novel studies demonstrate the positive impact of physical exercise in disorders marked by excessive impulsivity, including ADHD, affective disorders, schizophrenia, drug addictions, and Alzheimer’s disease (<xref ref-type="bibr" rid="B196">196</xref>–<xref ref-type="bibr" rid="B199">199</xref>).</p>
<p>The sequence of events that may lead to T2DM is believed to be initiated by decreased uptake of glucose into the skeletal muscle or insulin resistance, followed by hyperinsulinemia which in time exhausts the beta cells, leading to insulin deficiency and T2DM. The skeletal muscle (assisted by insulin) uptakes about 80% circulating glucose immediately after meals, rapidly clearing the postprandial hyperglycemia (<xref ref-type="bibr" rid="B200">200</xref>). Impaired glucose uptake, elevated blood glucose levels, and hyperinsulinemia comprise act one of the T2DM drama. From this point on, it may take decades before the pancreatic beta cells become insufficient and unable to secrete insulin that triggers act two: insulin deficiency and frank T2DM. As insulin is cosecreted with serotonin and dopamine, these MAs also become deficient, contributing to circulatory and cardiovascular pathology which frequently accompany T2DM (Figure <xref ref-type="fig" rid="F2">2</xref>).</p>
<p>Tryptophan is an essential amino acid and the sole precursor of the human body serotonin. The CNS manufactures its own serotonin; however, exogenous tryptophan must be supplied to the brain, a process facilitated by insulin. Deficiency of this hormone manifested by lower brain tryptophan was documented in patients with T2DM, possibly explaining the higher prevalence of depression in this metabolic disorder (<xref ref-type="bibr" rid="B201">201</xref>). In addition, tryptophan depletion studies in humans and animals demonstrated that low plasma tryptophan levels were associated with aggression (<xref ref-type="bibr" rid="B202">202</xref>–<xref ref-type="bibr" rid="B204">204</xref>).</p>
<p>Aside from serotonin, tryptophan is catabolized into several other neuroactive compounds, including the neurotoxic kynurenine (KYN) and the neuroprotective kynurenic acid (KYNA) (Figure <xref ref-type="fig" rid="F3">3</xref>).</p>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<p><bold>Dietary tryptophan is the precursor of proteins, serotonin, and the kynurenines</bold>. The exercise factor peroxisome proliferator-activated receptor-γ coactivator 1alpha (PGC-1alpha) released by the active skeletal muscle induces kynurenine aminotransferases (KAT), the enzyme responsible for the biosynthesis of the neuroprotective KYNA. In the absence of exercise, the neurotoxic KYN crosses the blood–brain barrier inducing psychopathology.</p>
</caption>
<graphic xlink:href="fpsyt-08-00020-g003"></graphic>
</fig>
<p>Kynurenine was demonstrated to cross the BBB and was implicated in the pathophysiology of disorders marked by impulsivity, including schizophrenia, ADHD, cognitive disorders, drug addictions, and mania (<xref ref-type="bibr" rid="B205">205</xref>). KYN is an antagonist at both the <italic>N</italic>-methyl-<sc>d</sc>-aspartate (NMDA) and alpha-7 nACh receptors, suggesting a possible pathoetiological mechanism of excessive impulsivity (<xref ref-type="bibr" rid="B206">206</xref>). This mechanism may be similar in nature to the antagonism at alpha-7 nACh receptors in POMC/CART neurons associated with weight gain and the T2DM risk (as referenced above in the discussion concerning smoking cessation).</p>
<p>It was recently demonstrated that the enzyme kynurenine aminotransferase (KAT) catalyzes the transformation of KYN into KYNA, in a reaction facilitated by the exercise factor PGC-1alpha (<xref ref-type="bibr" rid="B207">207</xref>) (Figure <xref ref-type="fig" rid="F3">3</xref>). As KYNA is neuroprotective, this molecular mechanism may provide an explanation for the known benefits of physical exercise in psychiatric disorders (<xref ref-type="bibr" rid="B208">208</xref>, <xref ref-type="bibr" rid="B209">209</xref>) (Figure <xref ref-type="fig" rid="F3">3</xref>).</p>
<p>While the beneficial effect of exercise and physical activity are well established, specific recommendations for the metabolic dysregulation and regimen details are beginning to emerge (Table <xref ref-type="table" rid="T2">2</xref>).</p>
</sec>
<sec id="S11">
<title>Conclusion: When the Seven Lean Cows Ate up the Seven Fat Cows</title>
<p>The energy–behavior link was intuited by the previous generations and currently we are merely rediscovering an old truth: the brain and energy are tightly interconnected. Indeed, the energy–hungry brain utilizes over 20% of the total body energy budget for the functioning of excitatory and inhibitory synapses believed to be dysregulated in impulsivity-connected psychopathology (<xref ref-type="bibr" rid="B210">210</xref>).</p>
<p>The metabolic hormones—leptin, adiponectin, and ghrelin—communicate the peripheral energy status to the hypothalamic feeding centers <italic>via</italic> receptors coexpressed with the major behavioral modulators, the MAs and ACh. As these receptors are blocked by the PTDs, they may become insensitive (for example, leptin resistance), inducing hypermetric hormonal responses with resultant obesity and metabolic dysregulation.</p>
<p>While PTDs may correct synaptic transmission, they alter the psychometabolic continuum, inducing weight gain in individuals already predisposed to it. Here, we suggest halting the development of metabolic dysregulation and obesity by initiating preventive treatment concurrently with the PTDs. Indeed, the management of impulsive aggression in psychiatric disorders may be incomplete without addressing the metabolic component and restoring the homeostasis of the psychometabolic continuum.</p>
<p>Addressing psychopathology and metabolic dysfunction simultaneously may result in superior outcomes compared to an intervention that addresses these conditions in a singular way. In addition, correcting energy homeostasis may lower the overall morbidity, mortality, and institutional cost in psychiatric population. A model can be inferred from clinical practice where it was found that correcting hypertension led to better outcomes in coronary artery disease, stroke, and renal failure compared to their <italic>post hoc</italic> treatment. After all, as prevention is preferable to treatment, what would be a valid reason for not addressing metabolic dysregulation in psychiatric patients in a preemptive manner?</p>
</sec>
<sec id="S12">
<title>Author Contributions</title>
<p>All the authors have contributed equally to this work.</p>
</sec>
<sec id="S13">
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer (RG) declared a past co-authorship with the authors to the handling editor and the reviewer (NS) declared her shared affiliation with the handling editor, who ensured that the process met the standards of a fair and objective review.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moeller</surname><given-names>FG</given-names></name><name><surname>Barratt</surname><given-names>ES</given-names></name><name><surname>Dougherty</surname><given-names>DM</given-names></name><name><surname>Schmitz</surname><given-names>JM</given-names></name><name><surname>Swann</surname><given-names>AC</given-names></name></person-group>. <article-title>Psychiatric aspects of impulsivity</article-title>. <source/>Am J Psychiatry (<year>2001</year>) <volume>158</volume>(<issue>11</issue>):<fpage>1783</fpage>–<lpage>93</lpage>.<pub-id pub-id-type="doi">10.1176/appi.ajp.158.11.1783</pub-id><pub-id pub-id-type="pmid">11691682</pub-id></mixed-citation>
</ref>
<ref id="B2">
<label>2</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Egea</surname><given-names>E</given-names></name><name><surname>Bernardo</surname><given-names>M</given-names></name><name><surname>Donner</surname><given-names>T</given-names></name><name><surname>Conget</surname><given-names>I</given-names></name><name><surname>Parellada</surname><given-names>E</given-names></name><name><surname>Justicia</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Metabolic profile of antipsychotic-naive individuals with non-affective psychosis</article-title>. <source/>Br J Psychiatry (<year>2009</year>) <volume>194</volume>(<issue>5</issue>):<fpage>434</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1192/bjp.bp.108.052605</pub-id><pub-id pub-id-type="pmid">19407273</pub-id></mixed-citation>
</ref>
<ref id="B3">
<label>3</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grover</surname><given-names>S</given-names></name><name><surname>Nebhinani</surname><given-names>N</given-names></name><name><surname>Chakrabarti</surname><given-names>S</given-names></name><name><surname>Parakh</surname><given-names>P</given-names></name><name><surname>Ghormode</surname><given-names>D</given-names></name></person-group>. <article-title>Metabolic syndrome in antipsychotic naïve patients diagnosed with schizophrenia</article-title>. <source/>Early Interv Psychiatry (<year>2012</year>) <volume>6</volume>(<issue>3</issue>):<fpage>326</fpage>–<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1111/j.1751-7893.2011.00321.x</pub-id><pub-id pub-id-type="pmid">22176701</pub-id></mixed-citation>
</ref>
<ref id="B4">
<label>4</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darcin</surname><given-names>EA</given-names></name><name><surname>Cavus</surname><given-names>YS</given-names></name><name><surname>Dilbaz</surname><given-names>N</given-names></name><name><surname>Kaya</surname><given-names>H</given-names></name><name><surname>Dogan</surname><given-names>E</given-names></name></person-group>. <article-title>Metabolic syndrome in drug-naïve and drug-free patients with schizophrenia and in their siblings</article-title>. <source/>Schizophr Res (<year>2015</year>) <volume>166</volume>(<issue>1–3</issue>):<fpage>201</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/j.schres.2015.05.004</pub-id><pub-id pub-id-type="pmid">26004686</pub-id></mixed-citation>
</ref>
<ref id="B5">
<label>5</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chadda</surname><given-names>RK</given-names></name><name><surname>Ramshankar</surname><given-names>P</given-names></name><name><surname>Deb</surname><given-names>KS</given-names></name><name><surname>Sood</surname><given-names>M</given-names></name></person-group>
<article-title>Metabolic syndrome in schizophrenia: differences between antipsychotic-naïve and treated patients</article-title>. <source/>J Pharmacol Pharmacother (<year>2013</year>) <volume>4</volume>(<issue>3</issue>):<fpage>176</fpage>–<lpage>86</lpage>.<pub-id pub-id-type="doi">10.4103/0976-500X.114596</pub-id><pub-id pub-id-type="pmid">23960422</pub-id></mixed-citation>
</ref>
<ref id="B6">
<label>6</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nasrallah</surname><given-names>HA</given-names></name><name><surname>Meyer</surname><given-names>JM</given-names></name><name><surname>Goff</surname><given-names>DC</given-names></name><name><surname>McEvoy</surname><given-names>JP</given-names></name><name><surname>Davis</surname><given-names>SM</given-names></name><name><surname>Stroup</surname><given-names>TS</given-names></name><etal></etal></person-group>
<article-title>Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline</article-title>. <source/>Schizophr Res (<year>2006</year>) <volume>86</volume>(<issue>1–3</issue>):<fpage>15</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1016/j.schres.2006.06.026</pub-id><pub-id pub-id-type="pmid">16884895</pub-id></mixed-citation>
</ref>
<ref id="B7">
<label>7</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>AJ</given-names></name><name><surname>Vancampfort</surname><given-names>D</given-names></name><name><surname>De Herdt</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>De Hert</surname><given-names>M</given-names></name></person-group>. <article-title>Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients</article-title>. <source/>Schizophr Bull (<year>2013</year>) <volume>39</volume>(<issue>2</issue>):<fpage>295</fpage>–<lpage>305</lpage>.<pub-id pub-id-type="doi">10.1093/schbul/sbs082</pub-id><pub-id pub-id-type="pmid">22927670</pub-id></mixed-citation>
</ref>
<ref id="B8">
<label>8</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name><name><surname>Lv</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name></person-group>
<article-title>The relationship between obesity and neurocognitive function in Chinese patients with schizophrenia</article-title>. <source/>BMC Psychiatry (<year>2013</year>) <volume>13</volume>:<fpage>109</fpage><pub-id pub-id-type="doi">10.1186/1471-244X-13-109</pub-id><pub-id pub-id-type="pmid">23570390</pub-id></mixed-citation>
</ref>
<ref id="B9">
<label>9</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beltrán-Sánchez</surname><given-names>H</given-names></name><name><surname>Harhay</surname><given-names>MO</given-names></name><name><surname>Harhay</surname><given-names>MM</given-names></name><name><surname>McElligott</surname><given-names>S</given-names></name></person-group>
<article-title>Prevalence and trends of metabolic syndrome in the adult US population, 1999–2010</article-title>. <source/>J Am Coll Cardiol (<year>2013</year>) <volume>62</volume>(<issue>8</issue>):<fpage>697</fpage>–<lpage>703</lpage>.<pub-id pub-id-type="doi">10.1016/j.jacc.2013.05.064</pub-id><pub-id pub-id-type="pmid">23810877</pub-id></mixed-citation>
</ref>
<ref id="B10">
<label>10</label>
<mixed-citation publication-type="book"><collab>World Health Organization</collab>. <source/>Obesity: Preventing and Managing the Global Epidemic. <publisher-loc>Geneva</publisher-loc>: <publisher-name>WHO</publisher-name> (<year>1998</year>).</mixed-citation>
</ref>
<ref id="B11">
<label>11</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merikangas</surname><given-names>KR</given-names></name><name><surname>Nakamura</surname><given-names>EF</given-names></name><name><surname>Kessler</surname><given-names>RC</given-names></name></person-group>. <article-title>Epidemiology of mental disorders in children and adolescents</article-title>. <source/>Dialogues Clin Neurosci (<year>2009</year>) <volume>11</volume>(<issue>1</issue>):<fpage>7</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="pmid">19432384</pub-id></mixed-citation>
</ref>
<ref id="B12">
<label>12</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sturm</surname><given-names>R</given-names></name><name><surname>Hattori</surname><given-names>A</given-names></name></person-group>
<article-title>Morbid obesity rates continue to rise rapidly in the US</article-title>. <source/>Int J Obes (<year>2013</year>) <volume>37</volume>(<issue>6</issue>):<fpage>889</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1038/ijo.2012.159</pub-id></mixed-citation>
</ref>
<ref id="B13">
<label>13</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirkpatrick</surname><given-names>B</given-names></name><name><surname>Miller</surname><given-names>B</given-names></name><name><surname>Garcia-Rizo</surname><given-names>C</given-names></name><name><surname>Fernandez-Egea</surname><given-names>E</given-names></name></person-group>. <article-title>Schizophrenia: a systemic disorder</article-title>. <source/>Clin Schizophr Relat Psychoses (<year>2014</year>) <volume>8</volume>:<fpage>73</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.3371/CSRP.KIMI.031513</pub-id><pub-id pub-id-type="pmid">23518782</pub-id></mixed-citation>
</ref>
<ref id="B14">
<label>14</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>BC</given-names></name><name><surname>Eisenberg</surname><given-names>D</given-names></name></person-group>. <article-title>Obesity, attention deficit-hyperactivity disorder and the dopaminergic reward system</article-title>. <source/>Coll Antropol (<year>2007</year>) <volume>31</volume>(<issue>1</issue>):<fpage>33</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">17600916</pub-id></mixed-citation>
</ref>
<ref id="B15">
<label>15</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>BI</given-names></name><name><surname>Liu</surname><given-names>S-M</given-names></name><name><surname>Zivkovic</surname><given-names>N</given-names></name><name><surname>Schaffer</surname><given-names>A</given-names></name><name><surname>Chien</surname><given-names>L-C</given-names></name><name><surname>Blanco</surname><given-names>C</given-names></name></person-group>. <article-title>The burden of obesity among adults with bipolar disorder in the United States</article-title>. <source/>Bipolar Disord (<year>2011</year>) <volume>13</volume>(<issue>4</issue>):<fpage>387</fpage>–<lpage>95</lpage>.<pub-id pub-id-type="doi">10.1111/j.1399-5618.2011.00932.x</pub-id><pub-id pub-id-type="pmid">21843278</pub-id></mixed-citation>
</ref>
<ref id="B16">
<label>16</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chouinard</surname><given-names>VA</given-names></name><name><surname>Pingali</surname><given-names>SM</given-names></name><name><surname>Chouinard</surname><given-names>G</given-names></name><name><surname>Henderson</surname><given-names>DC</given-names></name><name><surname>Mallya</surname><given-names>SG</given-names></name><name><surname>Cypess</surname><given-names>AM</given-names></name><etal></etal></person-group>
<article-title>Factors associated with overweight and obesity in schizophrenia, schizoaffective and bipolar disorders</article-title>. <source/>Psychiatry Res (<year>2016</year>) <volume>237</volume>:<fpage>304</fpage>–<lpage>10</lpage>.<pub-id pub-id-type="doi">10.1016/j.psychres.2016.01.024</pub-id><pub-id pub-id-type="pmid">26805561</pub-id></mixed-citation>
</ref>
<ref id="B17">
<label>17</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>B</given-names></name><name><surname>Klinitzke</surname><given-names>G</given-names></name><name><surname>Brähler</surname><given-names>E</given-names></name><name><surname>Kersting</surname><given-names>A</given-names></name></person-group>. <article-title>Extreme obesity is associated with suicidal behavior and suicide attempts in adults: results of a population-based representative sample</article-title>. <source/>Depress Anxiety (<year>2013</year>) <volume>30</volume>(<issue>10</issue>):<fpage>975</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1002/da.22105</pub-id><pub-id pub-id-type="pmid">23576272</pub-id></mixed-citation>
</ref>
<ref id="B18">
<label>18</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kakoschke</surname><given-names>N</given-names></name><name><surname>Kemps</surname><given-names>E</given-names></name><name><surname>Tiggemann</surname><given-names>M</given-names></name></person-group>. <article-title>External eating mediates the relationship between impulsivity and unhealthy food intake</article-title>. <source/>Physiol Behav (<year>2015</year>) <volume>147</volume>(<issue>1</issue>):<fpage>117</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="doi">10.1016/j.physbeh.2015.04.030</pub-id><pub-id pub-id-type="pmid">25911264</pub-id></mixed-citation>
</ref>
<ref id="B19">
<label>19</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sansone</surname><given-names>RA</given-names></name><name><surname>Sansone</surname><given-names>LA</given-names></name></person-group>. <article-title>The relationship between borderline personality and obesity</article-title>. <source/>Innov Clin Neurosci (<year>2013</year>) <volume>10</volume>(<issue>4</issue>):<fpage>36</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">23696958</pub-id></mixed-citation>
</ref>
<ref id="B20">
<label>20</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farhat</surname><given-names>T</given-names></name><name><surname>Iannotti</surname><given-names>RJ</given-names></name><name><surname>Simons-Morton</surname><given-names>B</given-names></name></person-group>. <article-title>Overweight, obesity, youth, and health-risk behaviors</article-title>. <source/>Am J Prev Med (<year>2010</year>) <volume>38</volume>(<issue>3</issue>):<fpage>258</fpage>–<lpage>67</lpage>.<pub-id pub-id-type="doi">10.1016/j.amepre.2009.10.038</pub-id><pub-id pub-id-type="pmid">20171527</pub-id></mixed-citation>
</ref>
<ref id="B21">
<label>21</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>EL</given-names></name><name><surname>Nousen</surname><given-names>L</given-names></name><name><surname>Chamlou</surname><given-names>K</given-names></name></person-group>. <article-title>Maternal high fat diet consumption during the perinatal period programs offspring behavior</article-title>. <source/>Physiol Behav (<year>2014</year>) <volume>123</volume>:<fpage>236</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1016/j.physbeh.2012.07.014</pub-id><pub-id pub-id-type="pmid">23085399</pub-id></mixed-citation>
</ref>
<ref id="B22">
<label>22</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fields</surname><given-names>SA</given-names></name><name><surname>Sabet</surname><given-names>M</given-names></name><name><surname>Reynolds</surname><given-names>B</given-names></name></person-group>. <article-title>Dimensions of impulsive behavior in obese, overweight, and healthy-weight adolescents</article-title>. <source/>Appetite (<year>2013</year>) <volume>70</volume>:<fpage>60</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/j.appet.2013.06.089</pub-id><pub-id pub-id-type="pmid">23831015</pub-id></mixed-citation>
</ref>
<ref id="B23">
<label>23</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golomb</surname><given-names>BA</given-names></name><name><surname>Evans</surname><given-names>MA</given-names></name><name><surname>White</surname><given-names>HL</given-names></name><name><surname>Dimsdale</surname><given-names>JE</given-names></name></person-group>. <article-title>Trans fat consumption and aggression</article-title>. <source/>PLoS One (<year>2012</year>) <volume>7</volume>(<issue>3</issue>):<fpage>e32175</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0032175</pub-id><pub-id pub-id-type="pmid">22403632</pub-id></mixed-citation>
</ref>
<ref id="B24">
<label>24</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>E</given-names></name><name><surname>Lippert</surname><given-names>AM</given-names></name></person-group>
<article-title>Neighborhood crime rate, weight-related behaviors, and obesity: a systematic review of the literature</article-title>. <source/>Sociol Comp (<year>2016</year>) <volume>10</volume>(<issue>3</issue>):<fpage>187</fpage>–<lpage>207</lpage>.<pub-id pub-id-type="doi">10.1111/soc4.12356</pub-id></mixed-citation>
</ref>
<ref id="B25">
<label>25</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shott</surname><given-names>ME</given-names></name><name><surname>Cornier</surname><given-names>MA</given-names></name><name><surname>Mittal</surname><given-names>VA</given-names></name><name><surname>Pryor</surname><given-names>TL</given-names></name><name><surname>Orr</surname><given-names>JM</given-names></name><name><surname>Brown</surname><given-names>MS</given-names></name><etal></etal></person-group>
<article-title>Orbitofrontal cortex volume and brain reward response in obesity</article-title>. <source/>Int J Obes (Lond) (<year>2015</year>) <volume>39</volume>(<issue>2</issue>):<fpage>214</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="doi">10.1038/ijo.2014.121</pub-id><pub-id pub-id-type="pmid">25027223</pub-id></mixed-citation>
</ref>
<ref id="B26">
<label>26</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horn</surname><given-names>NR</given-names></name><name><surname>Dolan</surname><given-names>M</given-names></name><name><surname>Elliott</surname><given-names>R</given-names></name><name><surname>Deakin</surname><given-names>JF</given-names></name><name><surname>Woodruff</surname><given-names>PW</given-names></name></person-group>. <article-title>Response inhibition and impulsivity: an fMRI study</article-title>. <source/>Neuropsychologia (<year>2003</year>) <volume>41</volume>(<issue>14</issue>):<fpage>1959</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="doi">10.1016/S0028-3932(03)00077-0</pub-id><pub-id pub-id-type="pmid">14572528</pub-id></mixed-citation>
</ref>
<ref id="B27">
<label>27</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batterink</surname><given-names>L</given-names></name><name><surname>Yokum</surname><given-names>S</given-names></name><name><surname>Stice</surname><given-names>E</given-names></name></person-group>. <article-title>Body mass correlates inversely with inhibitory control in response to food among adolescent girls: an fMRI study</article-title>. <source/>Neuroimage (<year>2010</year>) <volume>52</volume>(<issue>4</issue>):<fpage>1696</fpage>–<lpage>703</lpage>.<pub-id pub-id-type="doi">10.1016/j.neuroimage.2010.05.059</pub-id><pub-id pub-id-type="pmid">20510377</pub-id></mixed-citation>
</ref>
<ref id="B28">
<label>28</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoeckel</surname><given-names>LE</given-names></name><name><surname>Murdaugh</surname><given-names>DL</given-names></name><name><surname>Cox</surname><given-names>JE</given-names></name><name><surname>Cook</surname><given-names>EW</given-names></name><name><surname>Weller</surname><given-names>RE</given-names></name></person-group>. <article-title>Greater impulsivity is associated with decreased brain activation in obese women during a delay discounting task</article-title>. <source/>Brain Imaging Behav (<year>2013</year>) <volume>7</volume>(<issue>2</issue>):<fpage>116</fpage>–<lpage>28</lpage>.<pub-id pub-id-type="doi">10.1007/s11682-012-9201-4</pub-id><pub-id pub-id-type="pmid">22948956</pub-id></mixed-citation>
</ref>
<ref id="B29">
<label>29</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderberg</surname><given-names>RH</given-names></name><name><surname>Hansson</surname><given-names>C</given-names></name><name><surname>Fenander</surname><given-names>M</given-names></name><name><surname>Richard</surname><given-names>JE</given-names></name><name><surname>Dickson</surname><given-names>SL</given-names></name><name><surname>Nissbrandt</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>The stomach-derived hormone ghrelin increases impulsive behavior</article-title>. <source/>Neuropsychopharmacology (<year>2016</year>) <volume>41</volume>(<issue>5</issue>):<fpage>1199</fpage>–<lpage>209</lpage>.<pub-id pub-id-type="doi">10.1038/npp.2015.297</pub-id><pub-id pub-id-type="pmid">26424164</pub-id></mixed-citation>
</ref>
<ref id="B30">
<label>30</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutin</surname><given-names>AR</given-names></name><name><surname>Zonderman</surname><given-names>AB</given-names></name><name><surname>Uda</surname><given-names>M</given-names></name><name><surname>Deiana</surname><given-names>B</given-names></name><name><surname>Taub</surname><given-names>DD</given-names></name><name><surname>Longo</surname><given-names>DL</given-names></name><etal></etal></person-group>
<article-title>Personality traits and leptin</article-title>. <source/>Psychosom Med (<year>2013</year>) <volume>75</volume>(<issue>5</issue>):<fpage>505</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1097/PSY.0b013e3182919ff4</pub-id><pub-id pub-id-type="pmid">23697464</pub-id></mixed-citation>
</ref>
<ref id="B31">
<label>31</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atmaca</surname><given-names>M</given-names></name><name><surname>Kuloglu</surname><given-names>M</given-names></name><name><surname>Tezcan</surname><given-names>E</given-names></name><name><surname>Gecici</surname><given-names>O</given-names></name><name><surname>Ustundag</surname><given-names>B</given-names></name></person-group>. <article-title>Serum cholesterol and leptin levels in patients with borderline personality disorder</article-title>. <source/>Neuropsychobiology (<year>2002</year>) <volume>45</volume>(<issue>4</issue>):<fpage>167</fpage>–<lpage>71</lpage>.<pub-id pub-id-type="doi">10.1159/000063665</pub-id><pub-id pub-id-type="pmid">12097803</pub-id></mixed-citation>
</ref>
<ref id="B32">
<label>32</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tutuncu</surname><given-names>R</given-names></name><name><surname>Gunay</surname><given-names>H</given-names></name><name><surname>Balibey</surname><given-names>H</given-names></name><name><surname>Abaslı</surname><given-names>D</given-names></name></person-group>
<article-title>Decreased leptin levels in antisocial personality disorder patients</article-title>. <source/>Bull Clin Psychopharmacol (<year>2016</year>) <volume>26</volume>(<issue>3</issue>):<fpage>215</fpage>–<lpage>302</lpage>.<pub-id pub-id-type="doi">10.5455/bcp.20130127022613</pub-id></mixed-citation>
</ref>
<ref id="B33">
<label>33</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrini</surname><given-names>F</given-names></name><name><surname>Salio</surname><given-names>C</given-names></name><name><surname>Lossi</surname><given-names>L</given-names></name><name><surname>Merighi</surname><given-names>A</given-names></name></person-group>. <article-title>Ghrelin in central neurons</article-title>. <source/>Curr Neuropharmacol (<year>2009</year>) <volume>7</volume>(<issue>1</issue>):<fpage>37</fpage>–<lpage>49</lpage>.<pub-id pub-id-type="doi">10.2174/157015909787602779</pub-id><pub-id pub-id-type="pmid">19721816</pub-id></mixed-citation>
</ref>
<ref id="B34">
<label>34</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mavroconstanti</surname><given-names>T</given-names></name><name><surname>Halmøy</surname><given-names>A</given-names></name><name><surname>Haavik</surname><given-names>J</given-names></name></person-group>. <article-title>Decreased serum levels of adiponectin in adult attention deficit hyperactivity disorder</article-title>. <source/>Psychiatry Res (<year>2014</year>) <volume>216</volume>(<issue>1</issue>):<fpage>123</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="doi">10.1016/j.psychres.2014.01.025</pub-id><pub-id pub-id-type="pmid">24559850</pub-id></mixed-citation>
</ref>
<ref id="B35">
<label>35</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>YM</given-names></name><name><surname>Chen</surname><given-names>JY</given-names></name><name><surname>Yang</surname><given-names>WS</given-names></name><name><surname>Chi</surname><given-names>YC</given-names></name><name><surname>Liou</surname><given-names>YJ</given-names></name><name><surname>Lin</surname><given-names>CC</given-names></name><etal></etal></person-group>
<article-title>Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia</article-title>. <source/>J Clin Psychiatry (<year>2007</year>) <volume>68</volume>(<issue>12</issue>):<fpage>1834</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.4088/JCP.v68n1202</pub-id><pub-id pub-id-type="pmid">18162013</pub-id></mixed-citation>
</ref>
<ref id="B36">
<label>36</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>ML</given-names></name><name><surname>Wang</surname><given-names>TN</given-names></name><name><surname>Lin</surname><given-names>TY</given-names></name><name><surname>Shao</surname><given-names>WC</given-names></name><name><surname>Chang</surname><given-names>SH</given-names></name><name><surname>Chou</surname><given-names>JY</given-names></name><etal></etal></person-group>
<article-title>Differential effects of olanzapine and clozapine on plasma levels of adipocytokines and total ghrelin</article-title>. <source/>Prog Neuropsychopharmacol Biol Psychiatry (<year>2015</year>) <volume>58</volume>:<fpage>47</fpage>–<lpage>50</lpage>.<pub-id pub-id-type="doi">10.1016/j.pnpbp.2014.12.001</pub-id><pub-id pub-id-type="pmid">25496829</pub-id></mixed-citation>
</ref>
<ref id="B37">
<label>37</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>AK</given-names></name><name><surname>Bishop</surname><given-names>JR</given-names></name></person-group>. <article-title>Pharmacogenetics of leptin in antipsychotic-associated weight gain and obesity-related complications</article-title>. <source/>Pharmacogenomics (<year>2011</year>) <volume>12</volume>(<issue>7</issue>):<fpage>999</fpage>–<lpage>1016</lpage>.<pub-id pub-id-type="doi">10.2217/pgs.11.45</pub-id><pub-id pub-id-type="pmid">21787190</pub-id></mixed-citation>
</ref>
<ref id="B38">
<label>38</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freland</surname><given-names>L</given-names></name><name><surname>Beaulieu</surname><given-names>J-M</given-names></name></person-group>. <article-title>Inhibition of GSK3 by lithium, from single molecules to signaling networks</article-title>. <source/>Front Mol Neurosci (<year>2012</year>) <volume>5</volume>:<fpage>14</fpage>.<pub-id pub-id-type="doi">10.3389/fnmol.2012.00014</pub-id><pub-id pub-id-type="pmid">22363263</pub-id></mixed-citation>
</ref>
<ref id="B39">
<label>39</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacAulay</surname><given-names>K</given-names></name><name><surname>Woodgett</surname><given-names>JR</given-names></name></person-group>. <article-title>Targeting glycogen synthase kinase-3 (GSK-3) in the treatment of Type 2 diabetes</article-title>. <source/>Expert Opin Ther Targets (<year>2008</year>) <volume>12</volume>(<issue>10</issue>):<fpage>1265</fpage>–<lpage>74</lpage>.<pub-id pub-id-type="doi">10.1517/14728222.12.10.1265</pub-id><pub-id pub-id-type="pmid">18781825</pub-id></mixed-citation>
</ref>
<ref id="B40">
<label>40</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>C</given-names></name><name><surname>Hölscher</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>L</given-names></name></person-group>. <article-title>GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease</article-title>. <source/>Rev Neurosci (<year>2011</year>) <volume>23</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="doi">10.1515/rns.2011.061</pub-id><pub-id pub-id-type="pmid">22718609</pub-id></mixed-citation>
</ref>
<ref id="B41">
<label>41</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tutuncu</surname><given-names>R</given-names></name><name><surname>Gunay</surname><given-names>H</given-names></name><name><surname>Balibey</surname><given-names>H</given-names></name><name><surname>Abaslı</surname><given-names>D</given-names></name></person-group>
<article-title>Decreased leptin levels in antisocial personality disorder patients</article-title>. <source/>Bull Clin Psychopharmacol (<year>2013</year>) <volume>23</volume>(<issue>1</issue>):<fpage>72</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.5455/bcp.20130127022613</pub-id></mixed-citation>
</ref>
<ref id="B42">
<label>42</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohmura</surname><given-names>Y</given-names></name><name><surname>Tsutsui-Kimura</surname><given-names>I</given-names></name><name><surname>Yoshioka</surname><given-names>M</given-names></name></person-group>. <article-title>Impulsive behavior and nicotinic acetylcholine receptors</article-title>. <source/>J Pharmacol Sci (<year>2012</year>) <volume>118</volume>(<issue>4</issue>):<fpage>413</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1254/jphs.11R06CR</pub-id><pub-id pub-id-type="pmid">22447304</pub-id></mixed-citation>
</ref>
<ref id="B43">
<label>43</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polina</surname><given-names>ER</given-names></name><name><surname>Rovaris</surname><given-names>DL</given-names></name><name><surname>de Azeredo</surname><given-names>LA</given-names></name><name><surname>Mota</surname><given-names>NR</given-names></name><name><surname>Vitola</surname><given-names>ES</given-names></name><name><surname>Silva</surname><given-names>KL</given-names></name><etal></etal></person-group>
<article-title>ADHD diagnosis may influence the association between polymorphisms in nicotinic acetylcholine receptor genes and tobacco smoking</article-title>. <source/>Neuromolecular Med (<year>2014</year>) <volume>16</volume>(<issue>2</issue>):<fpage>389</fpage>–<lpage>97</lpage>.<pub-id pub-id-type="doi">10.1007/s12017-013-8286-2</pub-id><pub-id pub-id-type="pmid">24375168</pub-id></mixed-citation>
</ref>
<ref id="B44">
<label>44</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalley</surname><given-names>JW</given-names></name><name><surname>Roiser</surname><given-names>JP</given-names></name></person-group>. <article-title>Dopamine, serotonin and impulsivity</article-title>. <source/>Neuroscience (<year>2012</year>) <volume>215</volume>:<fpage>42</fpage>–<lpage>58</lpage>.<pub-id pub-id-type="doi">10.1016/j.neuroscience.2012.03.065</pub-id><pub-id pub-id-type="pmid">22542672</pub-id></mixed-citation>
</ref>
<ref id="B45">
<label>45</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khorassani</surname><given-names>FE</given-names></name><name><surname>Misher</surname><given-names>A</given-names></name><name><surname>Garris</surname><given-names>S</given-names></name></person-group>. <article-title>Past and present of antiobesity agents: focus on monoamine modulators</article-title>. <source/>Am J Health Syst Pharm (<year>2015</year>) <volume>72</volume>(<issue>9</issue>):<fpage>697</fpage>–<lpage>706</lpage>.<pub-id pub-id-type="doi">10.2146/ajhp140034</pub-id><pub-id pub-id-type="pmid">25873617</pub-id></mixed-citation>
</ref>
<ref id="B46">
<label>46</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donovan</surname><given-names>MH</given-names></name><name><surname>Tecott</surname><given-names>LH</given-names></name></person-group>. <article-title>Serotonin and the regulation of mammalian energy balance</article-title>. <source/>Front Neurosci (<year>2013</year>) <volume>7</volume>:<fpage>36</fpage>.<pub-id pub-id-type="doi">10.3389/fnins.2013.00036</pub-id><pub-id pub-id-type="pmid">23543912</pub-id></mixed-citation>
</ref>
<ref id="B47">
<label>47</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrivastava</surname><given-names>A</given-names></name><name><surname>Johnston</surname><given-names>ME</given-names></name></person-group>. <article-title>Weight-gain in psychiatric treatment: risks, implications, and strategies for prevention and management</article-title>. <source/>Mens Sana Monogr (<year>2010</year>) <volume>8</volume>(<issue>1</issue>):<fpage>53</fpage>–<lpage>68</lpage>.<pub-id pub-id-type="doi">10.4103/0973-1229.58819</pub-id><pub-id pub-id-type="pmid">21327170</pub-id></mixed-citation>
</ref>
<ref id="B48">
<label>48</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maayan</surname><given-names>L</given-names></name><name><surname>Correll</surname><given-names>CU</given-names></name></person-group>. <article-title>Management of antipsychotic-related weight gain</article-title>. <source/>Expert Rev Neurother (<year>2010</year>) <volume>10</volume>(<issue>7</issue>):<fpage>1175</fpage>–<lpage>200</lpage>.<pub-id pub-id-type="doi">10.1586/ern.10.85</pub-id><pub-id pub-id-type="pmid">20586697</pub-id></mixed-citation>
</ref>
<ref id="B49">
<label>49</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minor</surname><given-names>RK</given-names></name><name><surname>Chang</surname><given-names>JW</given-names></name><name><surname>de Cabo</surname><given-names>R</given-names></name></person-group>. <article-title>Hungry for life: how the arcuate nucleus and neuropeptide Y may play a critical role in mediating the benefits of calorie restriction</article-title>. <source/>Mol Cell Endocrinol (<year>2009</year>) <volume>299</volume>(<issue>1</issue>):<fpage>79</fpage>–<lpage>88</lpage>.<pub-id pub-id-type="doi">10.1016/j.mce.2008.10.044</pub-id><pub-id pub-id-type="pmid">19041366</pub-id></mixed-citation>
</ref>
<ref id="B50">
<label>50</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Picciotto</surname><given-names>MR</given-names></name><name><surname>Higley</surname><given-names>MJ</given-names></name><name><surname>Mineur</surname><given-names>YS</given-names></name></person-group>. <article-title>Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior</article-title>. <source/>Neuron (<year>2012</year>) <volume>76</volume>(<issue>1</issue>):<fpage>116</fpage>–<lpage>29</lpage>.<pub-id pub-id-type="doi">10.1016/j.neuron.2012.08.036</pub-id><pub-id pub-id-type="pmid">23040810</pub-id></mixed-citation>
</ref>
<ref id="B51">
<label>51</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adan</surname><given-names>RAH</given-names></name><name><surname>Tiesjema</surname><given-names>B</given-names></name><name><surname>Hillebrand</surname><given-names>JJG</given-names></name><name><surname>la Fleur</surname><given-names>SE</given-names></name><name><surname>Kas</surname><given-names>MJH</given-names></name><name><surname>de Krom</surname><given-names>M</given-names></name></person-group>. <article-title>The MC4 receptor and control of appetite</article-title>. <source/>Br J Pharmacol (<year>2006</year>) <volume>149</volume>(<issue>7</issue>):<fpage>815</fpage>–<lpage>27</lpage>.<pub-id pub-id-type="doi">10.1038/sj.bjp.0706929</pub-id><pub-id pub-id-type="pmid">17043670</pub-id></mixed-citation>
</ref>
<ref id="B52">
<label>52</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beaulieu</surname><given-names>JM</given-names></name><name><surname>Gainetdinov</surname><given-names>RR</given-names></name></person-group>. <article-title>The physiology, signaling, and pharmacology of dopamine receptors</article-title>. <source/>Pharmacol Rev (<year>2011</year>) <volume>63</volume>(<issue>1</issue>):<fpage>182</fpage>–<lpage>217</lpage>.<pub-id pub-id-type="doi">10.1124/pr.110.002642</pub-id><pub-id pub-id-type="pmid">21303898</pub-id></mixed-citation>
</ref>
<ref id="B53">
<label>53</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Generali</surname><given-names>JA</given-names></name><name><surname>Cada</surname><given-names>DJ</given-names></name></person-group>. <article-title>Topiramate: antipsychotic-induced weight gain</article-title>. <source/>Hosp Pharm (<year>2014</year>) <volume>49</volume>(<issue>4</issue>):<fpage>345</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1310/hpj4904-354</pub-id><pub-id pub-id-type="pmid">24958940</pub-id></mixed-citation>
</ref>
<ref id="B54">
<label>54</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>RR</given-names></name><name><surname>Zhang</surname><given-names>FY</given-names></name><name><surname>Gao</surname><given-names>KM</given-names></name><name><surname>Ou</surname><given-names>JJ</given-names></name><name><surname>Shao</surname><given-names>P</given-names></name><name><surname>Jin</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials</article-title>. <source/>Mol Psychiatry (<year>2016</year>) <volume>21</volume>(<issue>11</issue>):<fpage>1537</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1038/mp.2015.221</pub-id><pub-id pub-id-type="pmid">26809842</pub-id></mixed-citation>
</ref>
<ref id="B55">
<label>55</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Silva</surname><given-names>VA</given-names></name><name><surname>Suraweera</surname><given-names>C</given-names></name><name><surname>Ratnatunga</surname><given-names>SS</given-names></name><name><surname>Dayabandara</surname><given-names>M</given-names></name><name><surname>Wanniarachchi</surname><given-names>N</given-names></name><name><surname>Hanwella</surname><given-names>R</given-names></name></person-group>. <article-title>Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis</article-title>. <source/>BMC Psychiatry (<year>2016</year>) <volume>16</volume>:<fpage>341</fpage>.<pub-id pub-id-type="doi">10.1186/s12888-016-1049-5</pub-id><pub-id pub-id-type="pmid">27716110</pub-id></mixed-citation>
</ref>
<ref id="B56">
<label>56</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anagnostou</surname><given-names>E</given-names></name><name><surname>Aman</surname><given-names>MG</given-names></name><name><surname>Handen</surname><given-names>BL</given-names></name><name><surname>Sanders</surname><given-names>KB</given-names></name><name><surname>Shui</surname><given-names>A</given-names></name><name><surname>Hollway</surname><given-names>JA</given-names></name><etal></etal></person-group>
<article-title>Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autism spectrum disorder: a randomized clinical trial</article-title>. <source/>JAMA Psychiatry (<year>2016</year>) <volume>73</volume>(<issue>9</issue>):<fpage>928</fpage>–<lpage>37</lpage>.<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2016.1232</pub-id><pub-id pub-id-type="pmid">27556593</pub-id></mixed-citation>
</ref>
<ref id="B57">
<label>57</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Secher</surname><given-names>A</given-names></name><name><surname>Jelsing</surname><given-names>J</given-names></name><name><surname>Baquero</surname><given-names>AF</given-names></name><name><surname>Hecksher-Sørensen</surname><given-names>J</given-names></name><name><surname>Cowley</surname><given-names>MA</given-names></name><name><surname>Dalbøge</surname><given-names>LS</given-names></name><etal></etal></person-group>
<article-title>The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss</article-title>. <source/>J Clin Invest (<year>2014</year>) <volume>124</volume>(<issue>10</issue>):<fpage>4473</fpage>–<lpage>88</lpage>.<pub-id pub-id-type="doi">10.1172/JCI75276</pub-id><pub-id pub-id-type="pmid">25202980</pub-id></mixed-citation>
</ref>
<ref id="B58">
<label>58</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayfield</surname><given-names>K</given-names></name><name><surname>Siskind</surname><given-names>D</given-names></name><name><surname>Winckel</surname><given-names>K</given-names></name><name><surname>Russell</surname><given-names>AW</given-names></name><name><surname>Kisely</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>G</given-names></name><etal></etal></person-group>
<article-title>Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes</article-title>. <source/>J Psychopharmacol (<year>2016</year>) <volume>30</volume>(<issue>3</issue>):<fpage>227</fpage>–<lpage>36</lpage>.<pub-id pub-id-type="doi">10.1177/0269881115625496</pub-id><pub-id pub-id-type="pmid">26801056</pub-id></mixed-citation>
</ref>
<ref id="B59">
<label>59</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsen</surname><given-names>JR</given-names></name><name><surname>Vedtofte</surname><given-names>L</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>Oturai</surname><given-names>P</given-names></name><name><surname>Kjaer</surname><given-names>A</given-names></name><name><surname>Correll</surname><given-names>CU</given-names></name><etal></etal></person-group>
<article-title>Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial</article-title>. <source/>BMJ Open (<year>2014</year>) <volume>4</volume>(<issue>3</issue>):<fpage>e004227</fpage>.<pub-id pub-id-type="doi">10.1136/bmjopen-2013-004227</pub-id><pub-id pub-id-type="pmid">24667381</pub-id></mixed-citation>
</ref>
<ref id="B60">
<label>60</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishøy</surname><given-names>PL</given-names></name><name><surname>Knop</surname><given-names>FK</given-names></name><name><surname>Broberg</surname><given-names>BV</given-names></name><name><surname>Bak</surname><given-names>N</given-names></name><name><surname>Andersen</surname><given-names>UB</given-names></name><name><surname>Jørgensen</surname><given-names>NR</given-names></name><etal></etal></person-group>
<article-title>Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial</article-title>. <source/>Diabetes Obes Metab (<year>2017</year>) <volume>19</volume>(<issue>2</issue>):<fpage>162</fpage>–<lpage>71</lpage>.<pub-id pub-id-type="doi">10.1111/dom.12795</pub-id><pub-id pub-id-type="pmid">27717222</pub-id></mixed-citation>
</ref>
<ref id="B61">
<label>61</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebdrup</surname><given-names>BH</given-names></name><name><surname>Knop</surname><given-names>FK</given-names></name><name><surname>Madsen</surname><given-names>A</given-names></name><name><surname>Mortensen</surname><given-names>HB</given-names></name><name><surname>Søgaard</surname><given-names>B</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><etal></etal></person-group>
<article-title>Glucometabolic hormones and cardiovascular risk markers in antipsychotic-treated patients</article-title>. <source/>J Clin Psychiatry (<year>2014</year>) <volume>75</volume>(<issue>9</issue>):<fpage>e899</fpage>–<lpage>905</lpage>.<pub-id pub-id-type="doi">10.4088/JCP.13m08820</pub-id><pub-id pub-id-type="pmid">25295432</pub-id></mixed-citation>
</ref>
<ref id="B62">
<label>62</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>JG</given-names></name><name><surname>Park</surname><given-names>C-Y</given-names></name></person-group>
<article-title>Anti-obesity drugs: a review about their effects and safety</article-title>. <source/>Diabetes Metab J (<year>2012</year>) <volume>36</volume>(<issue>1</issue>):<fpage>13</fpage>–<lpage>25</lpage>.<pub-id pub-id-type="doi">10.4093/dmj.2012.36.1.13</pub-id><pub-id pub-id-type="pmid">22363917</pub-id></mixed-citation>
</ref>
<ref id="B63">
<label>63</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahrén</surname><given-names>B</given-names></name><name><surname>Johnson</surname><given-names>SL</given-names></name><name><surname>Stewart</surname><given-names>M</given-names></name><name><surname>Cirkel</surname><given-names>DT</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Perry</surname><given-names>C</given-names></name><etal></etal></person-group>
<article-title>HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin</article-title>. <source/>Diabetes Care (<year>2014</year>) <volume>37</volume>(<issue>8</issue>):<fpage>2141</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.2337/dc14-0024</pub-id><pub-id pub-id-type="pmid">24898304</pub-id></mixed-citation>
</ref>
<ref id="B64">
<label>64</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujioka</surname><given-names>K</given-names></name></person-group>. <article-title>Current and emerging medications for overweight or obesity in people with comorbidities</article-title>. <source/>Diabetes Obes Metab (<year>2015</year>) <volume>17</volume>(<issue>11</issue>):<fpage>1021</fpage>–<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1111/dom.12502</pub-id><pub-id pub-id-type="pmid">26040215</pub-id></mixed-citation>
</ref>
<ref id="B65">
<label>65</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vilsbøll</surname><given-names>T</given-names></name><name><surname>Christensen</surname><given-names>M</given-names></name><name><surname>Junker</surname><given-names>AE</given-names></name><name><surname>Knop</surname><given-names>FK</given-names></name><name><surname>Gluud</surname><given-names>LL</given-names></name></person-group>. <article-title>Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials</article-title>. <source/>BMJ (<year>2012</year>) <volume>344</volume>:<fpage>d7771</fpage>.<pub-id pub-id-type="doi">10.1136/bmj.d7771</pub-id><pub-id pub-id-type="pmid">22236411</pub-id></mixed-citation>
</ref>
<ref id="B66">
<label>66</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skibicka</surname><given-names>KP</given-names></name></person-group>. <article-title>The central GLP-1: implications for food and drug reward</article-title>. <source/>Front Neurosci (<year>2013</year>) <volume>7</volume>:<fpage>181</fpage>.<pub-id pub-id-type="doi">10.3389/fnins.2013.00181</pub-id><pub-id pub-id-type="pmid">24133407</pub-id></mixed-citation>
</ref>
<ref id="B67">
<label>67</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McIntyre</surname><given-names>RS</given-names></name><name><surname>Powell</surname><given-names>AM</given-names></name><name><surname>Kaidanovich-Beilin</surname><given-names>O</given-names></name><name><surname>Soczynska</surname><given-names>JK</given-names></name><name><surname>Alsuwaidan</surname><given-names>M</given-names></name><name><surname>Woldeyohannes</surname><given-names>HO</given-names></name><etal></etal></person-group>
<article-title>The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders</article-title>. <source/>Behav Brain Res (<year>2013</year>) <volume>237</volume>:<fpage>164</fpage>–<lpage>71</lpage>.<pub-id pub-id-type="doi">10.1016/j.bbr.2012.09.021</pub-id><pub-id pub-id-type="pmid">23000536</pub-id></mixed-citation>
</ref>
<ref id="B68">
<label>68</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gejl</surname><given-names>M</given-names></name><name><surname>Gjedde</surname><given-names>A</given-names></name><name><surname>Egefjord</surname><given-names>L</given-names></name><name><surname>Møller</surname><given-names>A</given-names></name><name><surname>Hansen</surname><given-names>SB</given-names></name><name><surname>Vang</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>In Alzheimer’s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial</article-title>. <source/>Front Aging Neurosci (<year>2016</year>) <volume>8</volume>:<fpage>108</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2016.00108</pub-id><pub-id pub-id-type="pmid">27252647</pub-id></mixed-citation>
</ref>
<ref id="B69">
<label>69</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schellekens</surname><given-names>H</given-names></name><name><surname>De Francesco</surname><given-names>PN</given-names></name><name><surname>Kandil</surname><given-names>D</given-names></name><name><surname>Theeuwes</surname><given-names>WF</given-names></name><name><surname>McCarthy</surname><given-names>T</given-names></name><name><surname>van Oeffelen</surname><given-names>WE</given-names></name><etal></etal></person-group>
<article-title>Ghrelin’s orexigenic effect is modulated via a serotonin 2C receptor interaction</article-title>. <source/>ACS Chem Neurosci (<year>2015</year>) <volume>6</volume>(<issue>7</issue>):<fpage>1186</fpage>–<lpage>97</lpage>.<pub-id pub-id-type="doi">10.1021/cn500318q</pub-id><pub-id pub-id-type="pmid">25727097</pub-id></mixed-citation>
</ref>
<ref id="B70">
<label>70</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palik</surname><given-names>E</given-names></name><name><surname>Birkás</surname><given-names>KD</given-names></name><name><surname>Faludi</surname><given-names>G</given-names></name><name><surname>Karádi</surname><given-names>I</given-names></name><name><surname>Cseh</surname><given-names>K</given-names></name></person-group>. <article-title>Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics</article-title>. <source/>Diabetes Res Clin Pract (<year>2005</year>) <volume>68</volume>(<issue>Suppl 1</issue>):<fpage>S60</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1016/j.diabres.2005.03.008</pub-id><pub-id pub-id-type="pmid">15955378</pub-id></mixed-citation>
</ref>
<ref id="B71">
<label>71</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agnoli</surname><given-names>L</given-names></name><name><surname>Carli</surname><given-names>M</given-names></name></person-group>. <article-title>Dorsal-striatal 5-HT2A and 5-HT2C receptors control impulsivity and perseverative responding in the 5-choice serial reaction time task</article-title>. <source/>Psychopharmacology (Berl) (<year>2012</year>) <volume>219</volume>(<issue>2</issue>):<fpage>633</fpage>–<lpage>45</lpage>.<pub-id pub-id-type="doi">10.1007/s00213-011-2581-0</pub-id><pub-id pub-id-type="pmid">22113450</pub-id></mixed-citation>
</ref>
<ref id="B72">
<label>72</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nonogaki</surname><given-names>K</given-names></name><name><surname>Ohashi-Nozue</surname><given-names>K</given-names></name><name><surname>Oka</surname><given-names>Y</given-names></name></person-group>. <article-title>A negative feedback system between brain serotonin systems and plasma active ghrelin levels in mice</article-title>. <source/>Biochem Biophys Res Commun (<year>2006</year>) <volume>341</volume>(<issue>3</issue>):<fpage>703</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/j.bbrc.2006.01.021</pub-id><pub-id pub-id-type="pmid">16430857</pub-id></mixed-citation>
</ref>
<ref id="B73">
<label>73</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fletcher</surname><given-names>PJ</given-names></name><name><surname>Soko</surname><given-names>AD</given-names></name><name><surname>Higgins</surname><given-names>GA</given-names></name></person-group>
<article-title>Impulsive action in the 5-choice serial reaction time test in 5-HT2C receptor null mutant mice</article-title>. <source/>Psychopharmacology (<year>2013</year>) <volume>226</volume>(<issue>Issue 3</issue>):<fpage>561</fpage>–<lpage>70</lpage>.<pub-id pub-id-type="doi">10.1007/s00213-012-2929-0</pub-id><pub-id pub-id-type="pmid">23192316</pub-id></mixed-citation>
</ref>
<ref id="B74">
<label>74</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navarra</surname><given-names>R</given-names></name><name><surname>Comery</surname><given-names>TA</given-names></name><name><surname>Graf</surname><given-names>R</given-names></name><name><surname>Rosenzweig-Lipson</surname><given-names>S</given-names></name><name><surname>Day</surname><given-names>M</given-names></name></person-group>. <article-title>The 5-HT(2C) receptor agonist WAY-163909 decreases impulsivity in the 5-choice serial reaction time test</article-title>. <source/>Behav Brain Res (<year>2008</year>) <volume>188</volume>(<issue>2</issue>):<fpage>412</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1016/j.bbr.2007.11.016</pub-id><pub-id pub-id-type="pmid">18191235</pub-id></mixed-citation>
</ref>
<ref id="B75">
<label>75</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doslikova</surname><given-names>B</given-names></name><name><surname>Garfield</surname><given-names>AS</given-names></name><name><surname>Shaw</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>ML</given-names></name><name><surname>Burdakov</surname><given-names>D</given-names></name><name><surname>Billups</surname><given-names>B</given-names></name><etal></etal></person-group>
<article-title>5-HT2C receptor agonist anorectic efficacy potentiated by 5-HT1B receptor agonist coapplication: an effect mediated via increased proportion of pro-opiomelanocortin neurons activated</article-title>. <source/>J Neurosci (<year>2013</year>) <volume>33</volume>(<issue>23</issue>):<fpage>9800</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1523/JNEUROSCI.4326-12.2013</pub-id><pub-id pub-id-type="pmid">23739976</pub-id></mixed-citation>
</ref>
<ref id="B76">
<label>76</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>MS</given-names></name><name><surname>Neumaier</surname><given-names>JF</given-names></name></person-group>. <article-title>The 5-HT1B receptor: behavioral implications</article-title>. <source/>Psychopharmacol Bull (<year>2001</year>) <volume>35</volume>(<issue>4</issue>):<fpage>170</fpage>–<lpage>85</lpage>.<pub-id pub-id-type="pmid">12397864</pub-id></mixed-citation>
</ref>
<ref id="B77">
<label>77</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anastasio</surname><given-names>NC</given-names></name><name><surname>Stutz</surname><given-names>SJ</given-names></name><name><surname>Fox</surname><given-names>RG</given-names></name><name><surname>Sears</surname><given-names>RM</given-names></name><name><surname>Emeson</surname><given-names>RB</given-names></name><name><surname>DiLeone</surname><given-names>RJ</given-names></name><etal></etal></person-group>
<article-title>Functional status of the serotonin 5-HT2C receptor (5-HT2CR) drives interlocked phenotypes that precipitate relapse-like behaviors in cocaine dependence</article-title>. <source/>Neuropsychopharmacology (<year>2014</year>) <volume>39</volume>(<issue>2</issue>):<fpage>370</fpage>–<lpage>82</lpage>.<pub-id pub-id-type="doi">10.1038/npp.2013.199</pub-id><pub-id pub-id-type="pmid">23939424</pub-id></mixed-citation>
</ref>
<ref id="B78">
<label>78</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nautiyal</surname><given-names>KM</given-names></name><name><surname>Tanaka</surname><given-names>KF</given-names></name><name><surname>Barr</surname><given-names>MM</given-names></name><name><surname>Tritschler</surname><given-names>L</given-names></name><name><surname>Le Dantec</surname><given-names>Y</given-names></name><name><surname>David</surname><given-names>DJ</given-names></name><etal></etal></person-group>
<article-title>Distinct circuits underlie the effects of 5-HT1B receptors on aggression and impulsivity</article-title>. <source/>Neuron (<year>2015</year>) <volume>86</volume>(<issue>3</issue>):<fpage>813</fpage>–<lpage>26</lpage>.<pub-id pub-id-type="doi">10.1016/j.neuron.2015.03.041</pub-id><pub-id pub-id-type="pmid">25892302</pub-id></mixed-citation>
</ref>
<ref id="B79">
<label>79</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olivier</surname><given-names>B</given-names></name><name><surname>van Oorschot</surname><given-names>R</given-names></name></person-group>. <article-title>5-HT1B receptors and aggression: a review</article-title>. <source/>Eur J Pharmacol (<year>2005</year>) <volume>526</volume>(<issue>1–3</issue>):<fpage>207</fpage>–<lpage>17</lpage>.<pub-id pub-id-type="doi">10.1016/j.ejphar.2005.09.066</pub-id><pub-id pub-id-type="pmid">16310769</pub-id></mixed-citation>
</ref>
<ref id="B80">
<label>80</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiménez</surname><given-names>E</given-names></name><name><surname>Arias</surname><given-names>B</given-names></name><name><surname>Mitjans</surname><given-names>M</given-names></name><name><surname>Goikolea</surname><given-names>JM</given-names></name><name><surname>Roda</surname><given-names>E</given-names></name><name><surname>Ruíz</surname><given-names>V</given-names></name><etal></etal></person-group>
<article-title>Association between GSK3β gene and increased impulsivity in bipolar disorder</article-title>. <source/>Eur Neuropsychopharmacol (<year>2014</year>) <volume>24</volume>(<issue>4</issue>):<fpage>510</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.euroneuro.2014.01.005</pub-id><pub-id pub-id-type="pmid">24486183</pub-id></mixed-citation>
</ref>
<ref id="B81">
<label>81</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koros</surname><given-names>E</given-names></name><name><surname>Dorner-Ciossek</surname><given-names>C</given-names></name></person-group>. <article-title>The role of glycogen synthase kinase-3beta in schizophrenia</article-title>. <source/>Drug News Perspect (<year>2007</year>) <volume>20</volume>(<issue>7</issue>):<fpage>437</fpage>–<lpage>45</lpage>.<pub-id pub-id-type="doi">10.1358/dnp.2007.20.7.1149632</pub-id><pub-id pub-id-type="pmid">17992266</pub-id></mixed-citation>
</ref>
<ref id="B82">
<label>82</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>X</given-names></name><name><surname>Rizavi</surname><given-names>HS</given-names></name><name><surname>Khan</surname><given-names>MA</given-names></name><name><surname>Dwivedi</surname><given-names>Y</given-names></name><name><surname>Pandey</surname><given-names>GN</given-names></name></person-group>. <article-title>Altered Wnt signalling in the teenage suicide brain: focus on glycogen synthase kinase-3β and β-catenin</article-title>. <source/>Int J Neuropsychopharmacol (<year>2013</year>) <volume>16</volume>(<issue>5</issue>):<fpage>945</fpage>–<lpage>55</lpage>.<pub-id pub-id-type="doi">10.1017/S1461145712001010</pub-id><pub-id pub-id-type="pmid">23110823</pub-id></mixed-citation>
</ref>
<ref id="B83">
<label>83</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polter</surname><given-names>AM</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group>. <article-title>Glycogen synthase kinase-3 is an intermediate modulator of serotonin neurotransmission</article-title>. <source/>Front Mol Neurosci (<year>2011</year>) <volume>4</volume>:<fpage>31</fpage>.<pub-id pub-id-type="doi">10.3389/fnmol.2011.00031</pub-id><pub-id pub-id-type="pmid">22028682</pub-id></mixed-citation>
</ref>
<ref id="B84">
<label>84</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oreña</surname><given-names>SJ</given-names></name><name><surname>Torchia</surname><given-names>AJ</given-names></name><name><surname>Robert</surname><given-names>S</given-names></name><name><surname>Garofalo</surname><given-names>RS</given-names></name></person-group>. <article-title>Inhibition of glycogen-synthase kinase 3 stimulates glycogen synthase and glucose transport by distinct mechanisms in 3T3-L1 adipocytes</article-title>. <source/>J Biol Chem (<year>2000</year>) <volume>275</volume>:<fpage>15765</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.M910002199</pub-id><pub-id pub-id-type="pmid">10748179</pub-id></mixed-citation>
</ref>
<ref id="B85">
<label>85</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Doble</surname><given-names>B</given-names></name><name><surname>Woodgett</surname><given-names>JR</given-names></name></person-group>. <article-title>Glycogen synthase kinase-3 in insulin and Wnt signalling: a double-edged sword?</article-title>
<source/>Biochem Soc Trans (<year>2004</year>) <volume>32</volume>(<issue>5</issue>):<fpage>803</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1042/BST0320803</pub-id><pub-id pub-id-type="pmid">15494020</pub-id></mixed-citation>
</ref>
<ref id="B86">
<label>86</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henriksen</surname><given-names>EJ</given-names></name><name><surname>Dokken</surname><given-names>BB</given-names></name></person-group>. <article-title>Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes</article-title>. <source/>Curr Drug Targets (<year>2006</year>) <volume>7</volume>(<issue>11</issue>):<fpage>1435</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="doi">10.2174/1389450110607011435</pub-id><pub-id pub-id-type="pmid">17100583</pub-id></mixed-citation>
</ref>
<ref id="B87">
<label>87</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Chao</surname><given-names>C</given-names></name></person-group>. <article-title>Assisting effects of lithium on hypoglycemic treatment in patients with diabetes</article-title>. <source/>Biol Trace Elem Res (<year>1997</year>) <volume>60</volume>(<issue>1–2</issue>):<fpage>131</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1007/BF02783316</pub-id><pub-id pub-id-type="pmid">9404682</pub-id></mixed-citation>
</ref>
<ref id="B88">
<label>88</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunt</surname><given-names>NT</given-names></name></person-group>
<article-title>Hypoglycemic effect of lithium</article-title>. <source/>Biol Psychiatry (<year>1987</year>) <volume>22</volume>:<fpage>798</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/0006-3223(87)90219-8</pub-id><pub-id pub-id-type="pmid">3593824</pub-id></mixed-citation>
</ref>
<ref id="B89">
<label>89</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saran</surname><given-names>AS</given-names></name></person-group>
<article-title>Antidiabetic effects of lithium</article-title>. <source/>J Clin Psychiatry (<year>1982</year>) <volume>43</volume>:<fpage>388</fpage>–<lpage>384</lpage>.</mixed-citation>
</ref>
<ref id="B90">
<label>90</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pijl</surname><given-names>H</given-names></name><name><surname>Ohashi</surname><given-names>S</given-names></name><name><surname>Matsuda</surname><given-names>M</given-names></name><name><surname>Miyazaki</surname><given-names>Y</given-names></name><name><surname>Mahankali</surname><given-names>A</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><etal></etal></person-group>
<article-title>Bromocriptine: a novel approach to the treatment of type 2 diabetes</article-title>. <source/>Diabetes Care (<year>2000</year>) <volume>23</volume>(<issue>8</issue>):<fpage>1154</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="doi">10.2337/diacare.23.8.1154</pub-id><pub-id pub-id-type="pmid">10937514</pub-id></mixed-citation>
</ref>
<ref id="B91">
<label>91</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>KA</given-names></name><name><surname>Gu</surname><given-names>H</given-names></name><name><surname>Lieberman</surname><given-names>JA</given-names></name><name><surname>Harp</surname><given-names>JB</given-names></name><name><surname>Perkins</surname><given-names>DO</given-names></name></person-group>. <article-title>Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine</article-title>. <source/>Am J Psychiatry (<year>2005</year>) <volume>162</volume>(<issue>9</issue>):<fpage>1744</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1176/appi.ajp.162.9.1744</pub-id><pub-id pub-id-type="pmid">16135638</pub-id></mixed-citation>
</ref>
<ref id="B92">
<label>92</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Praharaj</surname><given-names>SK</given-names></name><name><surname>Sharma</surname><given-names>PSVN</given-names></name></person-group>. <article-title>Amantadine for olanzapine-induced weight gain: a systematic review and meta-analysis of randomized placebo-controlled trials</article-title>. <source/>Ther Adv Psychopharmacol (<year>2012</year>) <volume>2</volume>(<issue>4</issue>):<fpage>151</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1177/2045125312440441</pub-id><pub-id pub-id-type="pmid">23983968</pub-id></mixed-citation>
</ref>
<ref id="B93">
<label>93</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandebourg</surname><given-names>T</given-names></name><name><surname>Hugo</surname><given-names>E</given-names></name><name><surname>Ben-Jonathan</surname><given-names>N</given-names></name></person-group>. <article-title>Adipocyte prolactin: regulation of release and putative functions</article-title>. <source/>Diabetes Obes Metab (<year>2007</year>) <volume>9</volume>(<issue>4</issue>):<fpage>464</fpage>–<lpage>76</lpage>.<pub-id pub-id-type="doi">10.1111/j.1463-1326.2006.00671.x</pub-id><pub-id pub-id-type="pmid">17587388</pub-id></mixed-citation>
</ref>
<ref id="B94">
<label>94</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>MS</given-names></name><name><surname>Song</surname><given-names>HC</given-names></name><name><surname>An</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Ko</surname><given-names>YH</given-names></name><name><surname>Jung</surname><given-names>IK</given-names></name><etal></etal></person-group>
<article-title>Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, single-blind, placebo-controlled, multicenter study</article-title>. <source/>Psychiatry Clin Neurosci (<year>2010</year>) <volume>64</volume>(<issue>1</issue>):<fpage>19</fpage>–<lpage>27</lpage>.<pub-id pub-id-type="doi">10.1111/j.1440-1819.2009.02032.x</pub-id><pub-id pub-id-type="pmid">19968833</pub-id></mixed-citation>
</ref>
<ref id="B95">
<label>95</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedrich</surname><given-names>N</given-names></name><name><surname>Schneider</surname><given-names>HJ</given-names></name><name><surname>Spielhagen</surname><given-names>C</given-names></name><name><surname>Markus</surname><given-names>MR</given-names></name><name><surname>Haring</surname><given-names>R</given-names></name><name><surname>Grabe</surname><given-names>HJ</given-names></name><etal></etal></person-group>
<article-title>The association of serum prolactin concentration with inflammatory biomarkers – cross-sectional findings from the population-based Study of Health in Pomerania</article-title>. <source/>Clin Endocrinol (Oxf) (<year>2011</year>) <volume>75</volume>(<issue>4</issue>):<fpage>561</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1111/j.1365-2265.2011.04075.x</pub-id><pub-id pub-id-type="pmid">21521343</pub-id></mixed-citation>
</ref>
<ref id="B96">
<label>96</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haring</surname><given-names>R</given-names></name><name><surname>Friedrich</surname><given-names>N</given-names></name><name><surname>Völzke</surname><given-names>H</given-names></name><name><surname>Vasan</surname><given-names>RS</given-names></name><name><surname>Felix</surname><given-names>SB</given-names></name><name><surname>Dörr</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Positive association of serum prolactin concentrations with all-cause and cardiovascular mortality</article-title>. <source/>Eur Heart J (<year>2014</year>) <volume>35</volume>(<issue>18</issue>):<fpage>1215</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="doi">10.1093/eurheartj/ehs23</pub-id><pub-id pub-id-type="pmid">22843444</pub-id></mixed-citation>
</ref>
<ref id="B97">
<label>97</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindenmayer</surname><given-names>JP</given-names></name><name><surname>Nasrallah</surname><given-names>H</given-names></name><name><surname>Pucci</surname><given-names>M</given-names></name><name><surname>James</surname><given-names>S</given-names></name><name><surname>Citrome</surname><given-names>L</given-names></name></person-group>. <article-title>A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities</article-title>. <source/>Schizophr Res (<year>2013</year>) <volume>147</volume>(<issue>2–3</issue>):<fpage>241</fpage>–<lpage>52</lpage>.<pub-id pub-id-type="doi">10.1016/j.schres.2013.03.01</pub-id><pub-id pub-id-type="pmid">23619055</pub-id></mixed-citation>
</ref>
<ref id="B98">
<label>98</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levi-Minzi</surname><given-names>S</given-names></name><name><surname>Bermanzohn</surname><given-names>PC</given-names></name><name><surname>Siris</surname><given-names>SG</given-names></name></person-group>
<article-title>Bromocriptine for “negative” schizophrenia</article-title>. <source/>Compr Psychiatry (<year>1991</year>) <volume>32</volume>(<issue>3</issue>):<fpage>210</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/0010-440X(91)90041-A</pub-id><pub-id pub-id-type="pmid">1679383</pub-id></mixed-citation>
</ref>
<ref id="B99">
<label>99</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gragnoli</surname><given-names>C</given-names></name><name><surname>Reeves</surname><given-names>GM</given-names></name><name><surname>Reazer</surname><given-names>J</given-names></name><name><surname>Postolache</surname><given-names>TT</given-names></name></person-group>
<article-title>Dopamine–prolactin pathway potentially contributes to the schizophrenia and type 2 diabetes comorbidity</article-title>. <source/>Transl Psychiatry (<year>2016</year>) <volume>6</volume>(<issue>4</issue>):<fpage>e785</fpage><pub-id pub-id-type="doi">10.1038/tp.2016.50</pub-id><pub-id pub-id-type="pmid">27093067</pub-id></mixed-citation>
</ref>
<ref id="B100">
<label>100</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poulton</surname><given-names>AS</given-names></name><name><surname>Hibbert</surname><given-names>EJ</given-names></name><name><surname>Champion</surname><given-names>BL</given-names></name><name><surname>Nanan</surname><given-names>RKH</given-names></name></person-group>. <article-title>Stimulants for the control of hedonic appetite</article-title>. <source/>Front Pharmacol (<year>2016</year>) <volume>7</volume>:<fpage>105</fpage>.<pub-id pub-id-type="doi">10.3389/fphar.2016.00105</pub-id><pub-id pub-id-type="pmid">27199749</pub-id></mixed-citation>
</ref>
<ref id="B101">
<label>101</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volkow</surname><given-names>ND</given-names></name><name><surname>Wang</surname><given-names>G-J</given-names></name><name><surname>Baler</surname><given-names>RD</given-names></name></person-group>. <article-title>Reward, dopamine and the control of food intake: implications for obesity</article-title>. <source/>Trends Cogn Sci (<year>2011</year>) <volume>15</volume>(<issue>1</issue>):<fpage>37</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="doi">10.1016/j.tics.2010.11.001</pub-id><pub-id pub-id-type="pmid">21109477</pub-id></mixed-citation>
</ref>
<ref id="B102">
<label>102</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>GJ</given-names></name><name><surname>Volkow</surname><given-names>ND</given-names></name><name><surname>Logan</surname><given-names>J</given-names></name><name><surname>Pappas</surname><given-names>NR</given-names></name><name><surname>Wong</surname><given-names>CT</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><etal></etal></person-group>
<article-title>Brain dopamine and obesity</article-title>. <source/>Lancet (<year>2001</year>) <volume>357</volume>:<fpage>354</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/S0140-6736(00)03643-6</pub-id><pub-id pub-id-type="pmid">11210998</pub-id></mixed-citation>
</ref>
<ref id="B103">
<label>103</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baik</surname><given-names>J-H</given-names></name></person-group>. <article-title>Dopamine signaling in food addiction: role of dopamine D2 receptors</article-title>. <source/>BMB Rep (<year>2013</year>) <volume>46</volume>(<issue>11</issue>):<fpage>519</fpage>–<lpage>26</lpage>.<pub-id pub-id-type="doi">10.5483/BMBRep.2013.46.11.207</pub-id><pub-id pub-id-type="pmid">24238362</pub-id></mixed-citation>
</ref>
<ref id="B104">
<label>104</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fornaro</surname><given-names>M</given-names></name><name><surname>Solmi</surname><given-names>M</given-names></name><name><surname>Perna</surname><given-names>G</given-names></name><name><surname>De Berardis</surname><given-names>D</given-names></name><name><surname>Veronese</surname><given-names>N</given-names></name><name><surname>Orsolini</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials</article-title>. <source/>Neuropsychiatr Dis Treat (<year>2016</year>) <volume>12</volume>:<fpage>1827</fpage>–<lpage>36</lpage>.<pub-id pub-id-type="doi">10.2147/NDT.S109637</pub-id><pub-id pub-id-type="pmid">27524900</pub-id></mixed-citation>
</ref>
<ref id="B105">
<label>105</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lasser</surname><given-names>RA</given-names></name><name><surname>Dirks</surname><given-names>B</given-names></name><name><surname>Nasrallah</surname><given-names>H</given-names></name><name><surname>Kirsch</surname><given-names>C</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Pucci</surname><given-names>ML</given-names></name><etal></etal></person-group>
<article-title>Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases</article-title>. <source/>Neuropsychopharmacology (<year>2013</year>) <volume>38</volume>(<issue>11</issue>):<fpage>2140</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1038/npp.2013.111</pub-id><pub-id pub-id-type="pmid">23756608</pub-id></mixed-citation>
</ref>
<ref id="B106">
<label>106</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meister</surname><given-names>B</given-names></name><name><surname>Gömüç</surname><given-names>B</given-names></name><name><surname>Suarez</surname><given-names>E</given-names></name><name><surname>Ishii</surname><given-names>Y</given-names></name><name><surname>Dürr</surname><given-names>K</given-names></name><name><surname>Gillberg</surname><given-names>L</given-names></name></person-group>. <article-title>Hypothalamic proopiomelanocortin (POMC) neurons have a cholinergic phenotype</article-title>. <source/>Eur J Neurosci (<year>2006</year>) <volume>24</volume>(<issue>10</issue>):<fpage>2731</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="doi">10.1111/j.1460-9568.2006.05157.x</pub-id><pub-id pub-id-type="pmid">17156199</pub-id></mixed-citation>
</ref>
<ref id="B107">
<label>107</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>Y-H</given-names></name><name><surname>Talmage</surname><given-names>DA</given-names></name><name><surname>Role</surname><given-names>LW</given-names></name></person-group>. <article-title>Nicotinic receptor-mediated effects on appetite and food intake</article-title>. <source/>J Neurobiol (<year>2002</year>) <volume>53</volume>(<issue>4</issue>):<fpage>618</fpage>–<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1002/neu.10147</pub-id><pub-id pub-id-type="pmid">12436425</pub-id></mixed-citation>
</ref>
<ref id="B108">
<label>108</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>W-L</given-names></name><name><surname>Gao</surname><given-names>X-B</given-names></name><name><surname>Picciotto</surname><given-names>MR</given-names></name></person-group>
<article-title>Acetylcholine acts through nicotinic receptors to enhance the firing rate of a subset of hypocretin neurons in the mouse hypothalamus through distinct presynaptic and postsynaptic mechanisms</article-title>. <source/>eNeuro (<year>2015</year>) <volume>2</volume>(<issue>1</issue>).<pub-id pub-id-type="doi">10.1523/ENEURO.0052-14.2015</pub-id></mixed-citation>
</ref>
<ref id="B109">
<label>109</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Diaz</surname><given-names>R</given-names></name><name><surname>Dando</surname><given-names>R</given-names></name><name><surname>Jacques-Silva</surname><given-names>MC</given-names></name><name><surname>Fachado</surname><given-names>A</given-names></name><name><surname>Molina</surname><given-names>J</given-names></name><name><surname>Abdulreda</surname><given-names>MH</given-names></name><etal></etal></person-group>
<article-title>Alpha cells secrete acetylcholine as a non-neuronal paracrine signal priming human beta cell function</article-title>. <source/>Nat Med (<year>2011</year>) <volume>17</volume>(<issue>7</issue>):<fpage>888</fpage>–<lpage>92</lpage>.<pub-id pub-id-type="doi">10.1038/nm.2371</pub-id><pub-id pub-id-type="pmid">21685896</pub-id></mixed-citation>
</ref>
<ref id="B110">
<label>110</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshikawa</surname><given-names>H</given-names></name><name><surname>Hellström-Lindahl</surname><given-names>E</given-names></name><name><surname>Grill</surname><given-names>V</given-names></name></person-group>. <article-title>Evidence for functional nicotinic receptors on pancreatic beta cells</article-title>. <source/>Metabolism (<year>2005</year>) <volume>54</volume>(<issue>2</issue>):<fpage>247</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="doi">10.1016/j.metabol.2004.08.020</pub-id><pub-id pub-id-type="pmid">15690320</pub-id></mixed-citation>
</ref>
<ref id="B111">
<label>111</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bymaster</surname><given-names>FP</given-names></name><name><surname>Felder</surname><given-names>CC</given-names></name><name><surname>Tzavara</surname><given-names>E</given-names></name><name><surname>Nomikos</surname><given-names>GG</given-names></name><name><surname>Calligaro</surname><given-names>DO</given-names></name><name><surname>Mckinzie</surname><given-names>DL</given-names></name></person-group>. <article-title>Muscarinic mechanisms of antipsychotic atypicality</article-title>. <source/>Prog Neuropsychopharmacol Biol Psychiatry (<year>2003</year>) <volume>27</volume>(<issue>7</issue>):<fpage>1125</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="doi">10.1016/j.pnpbp.2003.09.008</pub-id><pub-id pub-id-type="pmid">14642972</pub-id></mixed-citation>
</ref>
<ref id="B112">
<label>112</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bajaj</surname><given-names>M</given-names></name></person-group>
<article-title>Nicotine and insulin resistance: when the smoke clears</article-title>. <source/>Diabetes (<year>2012</year>) <volume>61</volume>(<issue>12</issue>):<fpage>3078</fpage>–<lpage>80</lpage>.<pub-id pub-id-type="doi">10.2337/db12-1100</pub-id><pub-id pub-id-type="pmid">23172960</pub-id></mixed-citation>
</ref>
<ref id="B113">
<label>113</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>AA</given-names></name><name><surname>Sridhar</surname><given-names>GR</given-names></name><name><surname>Das</surname><given-names>UN</given-names></name></person-group>. <article-title>Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer’s disease</article-title>. <source/>Med Hypotheses (<year>2007</year>) <volume>69</volume>(<issue>6</issue>):<fpage>1272</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/j.mehy.2007.03.032</pub-id><pub-id pub-id-type="pmid">17553629</pub-id></mixed-citation>
</ref>
<ref id="B114">
<label>114</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>VP</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Geng</surname><given-names>L</given-names></name><name><surname>Parks</surname><given-names>RJ</given-names></name><name><surname>Pang</surname><given-names>Y-P</given-names></name><name><surname>Brimijoin</surname><given-names>S</given-names></name></person-group>. <article-title>Plasma butyrylcholinesterase regulates ghrelin to control aggression</article-title>. <source/>Proc Natl Acad Sci U S A (<year>2015</year>) <volume>112</volume>(<issue>7</issue>):<fpage>2251</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.142153611</pub-id><pub-id pub-id-type="pmid">25646463</pub-id></mixed-citation>
</ref>
<ref id="B115">
<label>115</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marrero</surname><given-names>MB</given-names></name><name><surname>Lucas</surname><given-names>R</given-names></name><name><surname>Salet</surname><given-names>C</given-names></name><name><surname>Hauser</surname><given-names>TA</given-names></name><name><surname>Mazurov</surname><given-names>A</given-names></name><name><surname>Lippiello</surname><given-names>PM</given-names></name><etal></etal></person-group>
<article-title>An alpha7 nicotinic acetylcholine receptor-selective agonist reduces weight gain and metabolic changes in a mouse model of diabetes</article-title>. <source/>J Pharmacol Exp Ther (<year>2010</year>) <volume>332</volume>(<issue>1</issue>):<fpage>173</fpage>–<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1124/jpet.109.154633</pub-id><pub-id pub-id-type="pmid">19786623</pub-id></mixed-citation>
</ref>
<ref id="B116">
<label>116</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>JM</given-names></name><name><surname>Cummings</surname><given-names>MA</given-names></name><name><surname>Proctor</surname><given-names>G</given-names></name><name><surname>Stahl</surname><given-names>SM</given-names></name></person-group>. <article-title>Psychopharmacology of persistent violence and aggression</article-title>. <source/>Psychiatr Clin North Am (<year>2016</year>) <volume>39</volume>(<issue>4</issue>):<fpage>541</fpage>–<lpage>56</lpage>.<pub-id pub-id-type="doi">10.1016/j.psc.2016.07.012</pub-id><pub-id pub-id-type="pmid">27836150</pub-id></mixed-citation>
</ref>
<ref id="B117">
<label>117</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Figiel</surname><given-names>G</given-names></name><name><surname>Sadowsky</surname><given-names>C</given-names></name></person-group>. <article-title>A systematic review of the effectiveness of rivastigmine for the treatment of behavioral disturbances in dementia and other neurological disorders</article-title>. <source/>Curr Med Res Opin (<year>2008</year>) <volume>24</volume>(<issue>1</issue>):<fpage>157</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="doi">10.1185/030079908X260961</pub-id><pub-id pub-id-type="pmid">18036286</pub-id></mixed-citation>
</ref>
<ref id="B118">
<label>118</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brimijoin</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>VP</given-names></name><name><surname>Pang</surname><given-names>YP</given-names></name><name><surname>Geng</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name></person-group>. <article-title>Physiological roles for butyrylcholinesterase: a BChE-ghrelin axis</article-title>. <source/>Chem Biol Interact (<year>2016</year>) <volume>259</volume>(<issue>Pt B</issue>):<fpage>271</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1016/j.cbi.2016.02.013</pub-id><pub-id pub-id-type="pmid">26915976</pub-id></mixed-citation>
</ref>
<ref id="B119">
<label>119</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maier</surname><given-names>C</given-names></name><name><surname>Schaller</surname><given-names>G</given-names></name><name><surname>Buranyi</surname><given-names>B</given-names></name><name><surname>Luger</surname><given-names>A</given-names></name></person-group>. <article-title>The cholinergic system controls ghrelin release and ghrelin-induced growth hormone release in humans</article-title>. <source/>J Clin Endocrinol Metab (<year>2004</year>) <volume>89</volume>(<issue>9</issue>):<fpage>4729</fpage>–<lpage>33</lpage>.<pub-id pub-id-type="doi">10.1210/jc.2004-0656</pub-id><pub-id pub-id-type="pmid">15356087</pub-id></mixed-citation>
</ref>
<ref id="B120">
<label>120</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>M</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name></person-group>. <article-title>Mesolimbic leptin signaling negatively regulates cocaine-conditioned reward</article-title>. <source/>Transl Psychiatry (<year>2016</year>) <volume>6</volume>:<fpage>e972</fpage>.<pub-id pub-id-type="doi">10.1038/tp.2016.223</pub-id><pub-id pub-id-type="pmid">27922639</pub-id></mixed-citation>
</ref>
<ref id="B121">
<label>121</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cipolla-Neto</surname><given-names>J</given-names></name><name><surname>Amaral</surname><given-names>FG</given-names></name><name><surname>Afeche</surname><given-names>SC</given-names></name><name><surname>Tan</surname><given-names>DX</given-names></name><name><surname>Reiter</surname><given-names>RJ</given-names></name></person-group>. <article-title>Melatonin, energy metabolism, and obesity: a review</article-title>. <source/>J Pineal Res (<year>2014</year>) <volume>56</volume>(<issue>4</issue>):<fpage>371</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1111/jpi.12137</pub-id><pub-id pub-id-type="pmid">24654916</pub-id></mixed-citation>
</ref>
<ref id="B122">
<label>122</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haller</surname><given-names>G</given-names></name><name><surname>Kapoor</surname><given-names>M</given-names></name><name><surname>Budde</surname><given-names>J</given-names></name><name><surname>Xuei</surname><given-names>X</given-names></name><name><surname>Edenberg</surname><given-names>H</given-names></name><name><surname>Nurnberger</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Rare missense variants in CHRNB3 and CHRNA3 are associated with risk of alcohol and cocaine dependence</article-title>. <source/>Hum Mol Genet (<year>2014</year>) <volume>23</volume>(<issue>3</issue>):<fpage>810</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1093/hmg/ddt463</pub-id><pub-id pub-id-type="pmid">24057674</pub-id></mixed-citation>
</ref>
<ref id="B123">
<label>123</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamens</surname><given-names>HM</given-names></name><name><surname>Corley</surname><given-names>RP</given-names></name><name><surname>Richmond</surname><given-names>PA</given-names></name><name><surname>Darlington</surname><given-names>TM</given-names></name><name><surname>Dowell</surname><given-names>R</given-names></name><name><surname>Hopfer</surname><given-names>CJ</given-names></name><etal></etal></person-group>
<article-title>Evidence for association between low frequency variants in CHRNA6/CHRNB3 and antisocial drug dependence</article-title>. <source/>Behav Genet (<year>2016</year>) <volume>46</volume>(<issue>5</issue>):<fpage>693</fpage>–<lpage>704</lpage>.<pub-id pub-id-type="doi">10.1007/s10519-016-9792-4</pub-id><pub-id pub-id-type="pmid">27085880</pub-id></mixed-citation>
</ref>
<ref id="B124">
<label>124</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleisher</surname><given-names>C</given-names></name><name><surname>McGough</surname><given-names>J</given-names></name></person-group>. <article-title>Sofinicline: a novel nicotinic acetylcholine receptor agonist in the treatment of attention-deficit/hyperactivity disorder</article-title>. <source/>Expert Opin Investig Drugs (<year>2014</year>) <volume>23</volume>(<issue>8</issue>):<fpage>1157</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1517/13543784.2014.934806</pub-id><pub-id pub-id-type="pmid">24965900</pub-id></mixed-citation>
</ref>
<ref id="B125">
<label>125</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Fu</surname><given-names>W</given-names></name><name><surname>Wetter</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Guan</surname><given-names>Z</given-names></name><name><surname>Stuart</surname><given-names>P</given-names></name></person-group>
<article-title>Metabolism and disposition of ABT-894, a novel α4β2 neuronal acetylcholine receptor agonist, in mice and monkeys</article-title>. <source/>Xenobiotica (<year>2014</year>) <volume>44</volume>(<issue>6</issue>):<fpage>531</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="doi">10.3109/00498254.2013.855836</pub-id><pub-id pub-id-type="pmid">24479584</pub-id></mixed-citation>
</ref>
<ref id="B126">
<label>126</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowbotham</surname><given-names>MC</given-names></name><name><surname>Arslanian</surname><given-names>A</given-names></name><name><surname>Nothaft</surname><given-names>W</given-names></name><name><surname>Duan</surname><given-names>WR</given-names></name><name><surname>Best</surname><given-names>AE</given-names></name><name><surname>Pritchett</surname><given-names>Y</given-names></name><etal></etal></person-group>
<article-title>Efficacy and safety of the α4β2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain</article-title>. <source/>Pain (<year>2012</year>) <volume>153</volume>(<issue>4</issue>):<fpage>862</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.pain.2012.01.009</pub-id><pub-id pub-id-type="pmid">22386472</pub-id></mixed-citation>
</ref>
<ref id="B127">
<label>127</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martínez de Morentin</surname><given-names>PB</given-names></name><name><surname>Whittle</surname><given-names>AJ</given-names></name><name><surname>Fernø</surname><given-names>J</given-names></name><name><surname>Nogueiras</surname><given-names>R</given-names></name><name><surname>Diéguez</surname><given-names>C</given-names></name><name><surname>Vidal-Puig</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Nicotine induces negative energy balance through hypothalamic AMP-activated protein kinase</article-title>. <source/>Diabetes (<year>2012</year>) <volume>61</volume>(<issue>4</issue>):<fpage>807</fpage>–<lpage>17</lpage>.<pub-id pub-id-type="doi">10.2337/db11-1079</pub-id><pub-id pub-id-type="pmid">22315316</pub-id></mixed-citation>
</ref>
<ref id="B128">
<label>128</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kageyama</surname><given-names>H</given-names></name><name><surname>Takenoya</surname><given-names>F</given-names></name><name><surname>Shiba</surname><given-names>K</given-names></name><name><surname>Shioda</surname><given-names>S</given-names></name></person-group>. <article-title>Neuronal circuits involving ghrelin in the hypothalamus-mediated regulation of feeding</article-title>. <source/>Neuropeptides (<year>2010</year>) <volume>44</volume>(<issue>2</issue>):<fpage>133</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.npep.2009.11.010</pub-id><pub-id pub-id-type="pmid">20036003</pub-id></mixed-citation>
</ref>
<ref id="B129">
<label>129</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghigo</surname><given-names>E</given-names></name><name><surname>Broglio</surname><given-names>F</given-names></name><name><surname>Arvat</surname><given-names>E</given-names></name><name><surname>Maccario</surname><given-names>M</given-names></name><name><surname>Papotti</surname><given-names>M</given-names></name><name><surname>Muccioli</surname><given-names>G</given-names></name></person-group>. <article-title>Ghrelin: more than a natural GH secretagogue and/or an orexigenic factor</article-title>. <source/>Clin Endocrinol (<year>2005</year>) <volume>62</volume>:<fpage>1</fpage>–<lpage>17</lpage>.<pub-id pub-id-type="doi">10.1111/j.1365-2265.2004.02160.x</pub-id><pub-id pub-id-type="pmid">15638864</pub-id></mixed-citation>
</ref>
<ref id="B130">
<label>130</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horvath</surname><given-names>TL</given-names></name><name><surname>Diano</surname><given-names>S</given-names></name><name><surname>Sotonyi</surname><given-names>P</given-names></name><name><surname>Heiman</surname><given-names>M</given-names></name><name><surname>Tschop</surname><given-names>M</given-names></name></person-group>
<article-title>Minireview: ghrelin and the regulation of energy balance – a hypothalamic perspective</article-title>. <source/>Endocrinology (<year>2001</year>) <volume>142</volume>:<fpage>4163</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1210/en.142.10.4163</pub-id><pub-id pub-id-type="pmid">11564668</pub-id></mixed-citation>
</ref>
<ref id="B131">
<label>131</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montastruc</surname><given-names>F</given-names></name><name><surname>Palmaro</surname><given-names>A</given-names></name><name><surname>Bagheri</surname><given-names>H</given-names></name><name><surname>Schmitt</surname><given-names>L</given-names></name><name><surname>Montastruc</surname><given-names>JL</given-names></name><name><surname>Lapeyre-Mestre</surname><given-names>M</given-names></name></person-group>. <article-title>Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: a pharmacoepidemiological-pharmacodynamic study in VigiBase</article-title>. <source/>Eur Neuropsychopharmacol (<year>2015</year>) <volume>25</volume>(<issue>10</issue>):<fpage>1556</fpage>–<lpage>65</lpage>.<pub-id pub-id-type="doi">10.1016/j.euroneuro.2015.07.010</pub-id><pub-id pub-id-type="pmid">26256010</pub-id></mixed-citation>
</ref>
<ref id="B132">
<label>132</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>F</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Kong</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Meng</surname><given-names>H</given-names></name><name><surname>Spaeth</surname><given-names>RB</given-names></name><etal></etal></person-group>
<article-title>Effect of transcutaneous auricular vagus nerve stimulation on impaired glucose tolerance: a pilot randomized study</article-title>. <source/>BMC Complement Altern Med (<year>2014</year>) <volume>14</volume>:<fpage>203</fpage>.<pub-id pub-id-type="doi">10.1186/1472-6882-14-203</pub-id><pub-id pub-id-type="pmid">24968966</pub-id></mixed-citation>
</ref>
<ref id="B133">
<label>133</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pini</surname><given-names>A</given-names></name><name><surname>Obara</surname><given-names>I</given-names></name><name><surname>Battell</surname><given-names>E</given-names></name><name><surname>Chazot</surname><given-names>PL</given-names></name><name><surname>Rosa</surname><given-names>AC</given-names></name></person-group>. <article-title>Histamine in diabetes: is it time to reconsider?</article-title>
<source/>Pharmacol Res (<year>2016</year>) <volume>111</volume>:<fpage>316</fpage>–<lpage>24</lpage>.<pub-id pub-id-type="doi">10.1016/j.phrs.2016.06.021</pub-id><pub-id pub-id-type="pmid">27343700</pub-id></mixed-citation>
</ref>
<ref id="B134">
<label>134</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>C</given-names></name><name><surname>Weston-Green</surname><given-names>K</given-names></name><name><surname>Huang</surname><given-names>XF</given-names></name></person-group>. <article-title>The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?</article-title>
<source/>Prog Neuropsychopharmacol Biol Psychiatry (<year>2010</year>) <volume>34</volume>:<fpage>1</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1016/j.pnpbp.2009.11.009</pub-id><pub-id pub-id-type="pmid">19922755</pub-id></mixed-citation>
</ref>
<ref id="B135">
<label>135</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masaki</surname><given-names>T</given-names></name><name><surname>Chiba</surname><given-names>S</given-names></name><name><surname>Yasuda</surname><given-names>T</given-names></name><name><surname>Noguchi</surname><given-names>H</given-names></name><name><surname>Kakuma</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><etal></etal></person-group>
<article-title>Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity</article-title>. <source/>Diabetes (<year>2004</year>) <volume>53</volume>(<issue>9</issue>):<fpage>2250</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="doi">10.2337/diabetes.53.9.2250</pub-id><pub-id pub-id-type="pmid">15331534</pub-id></mixed-citation>
</ref>
<ref id="B136">
<label>136</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barak</surname><given-names>N</given-names></name><name><surname>Greenway</surname><given-names>FL</given-names></name><name><surname>Fujioka</surname><given-names>K</given-names></name><name><surname>Aronne</surname><given-names>LJ</given-names></name><name><surname>Kushner</surname><given-names>RF</given-names></name></person-group>. <article-title>Effect of histaminergic manipulation on weight in obese adults: a randomized placebo controlled trial</article-title>. <source/>Int J Obes (Lond) (<year>2008</year>) <volume>32</volume>(<issue>10</issue>):<fpage>1559</fpage>–<lpage>65</lpage>.<pub-id pub-id-type="doi">10.1038/ijo.2008.135</pub-id><pub-id pub-id-type="pmid">18698316</pub-id></mixed-citation>
</ref>
<ref id="B137">
<label>137</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>AH</given-names></name><name><surname>Yanoff</surname><given-names>LB</given-names></name><name><surname>Stern</surname><given-names>EA</given-names></name><name><surname>Akomeah</surname><given-names>A</given-names></name><name><surname>Courville</surname><given-names>A</given-names></name><name><surname>Kozlosky</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Acute effects of betahistine hydrochloride on food intake and appetite in obese women: a randomized, placebo-controlled trial</article-title>. <source/>Am J Clin Nutr (<year>2010</year>) <volume>92</volume>(<issue>6</issue>):<fpage>1290</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.3945/ajcn.110.001586</pub-id><pub-id pub-id-type="pmid">20881066</pub-id></mixed-citation>
</ref>
<ref id="B138">
<label>138</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lian</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>X-F</given-names></name><name><surname>Pai</surname><given-names>N</given-names></name><name><surname>Deng</surname><given-names>C</given-names></name></person-group>. <article-title>Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment</article-title>. <source/>PLoS One (<year>2014</year>) <volume>9</volume>(<issue>8</issue>):<fpage>e104160</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0104160</pub-id><pub-id pub-id-type="pmid">25084453</pub-id></mixed-citation>
</ref>
<ref id="B139">
<label>139</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadek</surname><given-names>B</given-names></name><name><surname>Khanian</surname><given-names>SS</given-names></name><name><surname>Ashoor</surname><given-names>A</given-names></name><name><surname>Prytkova</surname><given-names>T</given-names></name><name><surname>Ghattas</surname><given-names>MA</given-names></name><name><surname>Atatreh</surname><given-names>N</given-names></name><etal></etal></person-group>
<article-title>Effects of antihistamines on the function of human α7-nicotinic acetylcholine receptors</article-title>. <source/>Eur J Pharmacol (<year>2015</year>) <volume>746</volume>:<fpage>308</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="doi">10.1016/j.ejphar.2014.10.046</pub-id><pub-id pub-id-type="pmid">25445036</pub-id></mixed-citation>
</ref>
<ref id="B140">
<label>140</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gotoh</surname><given-names>K</given-names></name><name><surname>Fukagawa</surname><given-names>K</given-names></name><name><surname>Fukagawa</surname><given-names>T</given-names></name><name><surname>Noguchi</surname><given-names>H</given-names></name><name><surname>Kakuma</surname><given-names>T</given-names></name><name><surname>Sakata</surname><given-names>T</given-names></name><etal></etal></person-group>
<article-title>Hypothalamic neuronal histamine mediates the thyrotropin-releasing hormone-induced suppression of food intake</article-title>. <source/>J Neurochem (<year>2007</year>) <volume>103</volume>(<issue>3</issue>):<fpage>1102</fpage>–<lpage>10</lpage>.<pub-id pub-id-type="doi">10.1111/j.1471-4159.2007.04802.x</pub-id><pub-id pub-id-type="pmid">17760865</pub-id></mixed-citation>
</ref>
<ref id="B141">
<label>141</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshimatsu</surname><given-names>H</given-names></name><name><surname>Itateyama</surname><given-names>E</given-names></name><name><surname>Kondou</surname><given-names>S</given-names></name><name><surname>Tajima</surname><given-names>D</given-names></name><name><surname>Himeno</surname><given-names>K</given-names></name><name><surname>Hidaka</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Hypothalamic neuronal histamine as a target of leptin in feeding behavior</article-title>. <source/>Diabetes (<year>1999</year>) <volume>48</volume>(<issue>12</issue>):<fpage>2286</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="doi">10.2337/diabetes.48.12.2286</pub-id><pub-id pub-id-type="pmid">10580415</pub-id></mixed-citation>
</ref>
<ref id="B142">
<label>142</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parks</surname><given-names>GS</given-names></name><name><surname>Olivas</surname><given-names>ND</given-names></name><name><surname>Ikrar</surname><given-names>T</given-names></name><name><surname>Sanathara</surname><given-names>NM</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><etal></etal></person-group>
<article-title>Histamine inhibits the melanin-concentrating hormone system: implications for sleep and arousal</article-title>. <source/>J Physiol (<year>2014</year>) <volume>592</volume>(<issue>10</issue>):<fpage>2183</fpage>–<lpage>96</lpage>.<pub-id pub-id-type="doi">10.1113/jphysiol.2013.268771</pub-id><pub-id pub-id-type="pmid">24639485</pub-id></mixed-citation>
</ref>
<ref id="B143">
<label>143</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Igawa</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Kakegawa</surname><given-names>K</given-names></name><name><surname>Kina</surname><given-names>A</given-names></name><name><surname>Ikoma</surname><given-names>M</given-names></name><name><surname>Aida</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Melanin-concentrating hormone receptor 1 antagonists lacking an aliphatic amine: synthesis and structure-activity relationships of novel 1-(Imidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one derivatives</article-title>. <source/>J Med Chem (<year>2016</year>) <volume>59</volume>(<issue>3</issue>):<fpage>1116</fpage>–<lpage>39</lpage>.<pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b01704</pub-id><pub-id pub-id-type="pmid">26736071</pub-id></mixed-citation>
</ref>
<ref id="B144">
<label>144</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henry</surname><given-names>MB</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Duan</surname><given-names>C</given-names></name><name><surname>Patel</surname><given-names>B</given-names></name><name><surname>Vassileva</surname><given-names>G</given-names></name><name><surname>Sondey</surname><given-names>C</given-names></name><etal></etal></person-group>
<article-title>Antidiabetic properties of the histamine H3 receptor protean agonist proxyfan</article-title>. <source/>Endocrinology (<year>2011</year>) <volume>152</volume>(<issue>3</issue>):<fpage>828</fpage>–<lpage>35</lpage>.<pub-id pub-id-type="doi">10.1210/en.2010-0757</pub-id><pub-id pub-id-type="pmid">21239440</pub-id></mixed-citation>
</ref>
<ref id="B145">
<label>145</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>AU</given-names></name><name><surname>Shao</surname><given-names>N</given-names></name><name><surname>Aslanian</surname><given-names>RG</given-names></name><name><surname>Chan</surname><given-names>TY</given-names></name><name><surname>Degrado</surname><given-names>SJ</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>Discovery of a potent thiadiazole class of histamine H3 receptor antagonist for the treatment of diabetes</article-title>. <source/>ACS Med Chem Lett (<year>2012</year>) <volume>3</volume>(<issue>3</issue>):<fpage>198</fpage>–<lpage>202</lpage>.<pub-id pub-id-type="doi">10.1021/ml200250t</pub-id><pub-id pub-id-type="pmid">24900450</pub-id></mixed-citation>
</ref>
<ref id="B146">
<label>146</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cacabelos</surname><given-names>R</given-names></name></person-group>
<article-title>Histamine: the missing link in the pathogenesis of some brain disorders</article-title>. <source/>J Clin Exp Neuroimmunol (<year>2016</year>) <volume>1</volume>:<fpage>103</fpage><pub-id pub-id-type="doi">10.4172/jceni.1000103</pub-id></mixed-citation>
</ref>
<ref id="B147">
<label>147</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahmood</surname><given-names>D</given-names></name></person-group>. <article-title>Histamine H3 receptors and its antagonism as a novel mechanism for antipsychotic effect: a current preclinical &amp; clinical perspective</article-title>. <source/>Int J Health Sci (<year>2016</year>) <volume>10</volume>(<issue>4</issue>):<fpage>564</fpage>–<lpage>75</lpage>.<pub-id pub-id-type="pmid">27833522</pub-id></mixed-citation>
</ref>
<ref id="B148">
<label>148</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vohora</surname><given-names>D</given-names></name><name><surname>Bhowmik</surname><given-names>M</given-names></name></person-group>
<article-title>Histamine H3 receptor antagonists/inverse agonists on cognitive and motor processes: relevance to Alzheimer’s disease, ADHD, schizophrenia, and drug abuse</article-title>. <source/>Front Syst Neurosci (<year>2012</year>) <volume>6</volume>:<fpage>72</fpage><pub-id pub-id-type="doi">10.3389/fnsys.2012.00072</pub-id><pub-id pub-id-type="pmid">23109919</pub-id></mixed-citation>
</ref>
<ref id="B149">
<label>149</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellenbroek</surname><given-names>BA</given-names></name></person-group>
<article-title>Histamine H3 receptors, the complex interaction with dopamine and its implications for addiction</article-title>. <source/>Br J Pharmacol (<year>2013</year>) <volume>170</volume>(<issue>1</issue>):<fpage>46</fpage>–<lpage>57</lpage>.<pub-id pub-id-type="doi">10.1111/bph.12221</pub-id><pub-id pub-id-type="pmid">23647606</pub-id></mixed-citation>
</ref>
<ref id="B150">
<label>150</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lethbridge</surname><given-names>NL</given-names></name><name><surname>Chazot</surname><given-names>PL</given-names></name></person-group>. <article-title>Ligand autoradiographical quantification of histamine H3 receptor in human dementia with Lewy bodies</article-title>. <source/>Pharmacol Res (<year>2016</year>) <volume>113</volume>(<issue>Pt A</issue>):<fpage>245</fpage>–<lpage>56</lpage>.<pub-id pub-id-type="doi">10.1016/j.phrs.2016.08.034</pub-id><pub-id pub-id-type="pmid">27592250</pub-id></mixed-citation>
</ref>
<ref id="B151">
<label>151</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esbenshade</surname><given-names>TA</given-names></name><name><surname>Browman</surname><given-names>KE</given-names></name><name><surname>Bitner</surname><given-names>RS</given-names></name><name><surname>Strakhova</surname><given-names>M</given-names></name><name><surname>Cowart</surname><given-names>MD</given-names></name><name><surname>Brioni</surname><given-names>JD</given-names></name></person-group>. <article-title>The histamine H3 receptor: an attractive target for the treatment of cognitive disorders</article-title>. <source/>Br J Pharmacol (<year>2008</year>) <volume>154</volume>(<issue>6</issue>):<fpage>1166</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1038/bjp.2008.147</pub-id><pub-id pub-id-type="pmid">18469850</pub-id></mixed-citation>
</ref>
<ref id="B152">
<label>152</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weisler</surname><given-names>RH</given-names></name><name><surname>Pandina</surname><given-names>GJ</given-names></name><name><surname>Daly</surname><given-names>EJ</given-names></name><name><surname>Cooper</surname><given-names>K</given-names></name><name><surname>Gassmann-Mayer</surname><given-names>C</given-names></name><collab>31001074-ATT2001 Study Investigators</collab></person-group>. <article-title>Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder</article-title>. <source/>CNS Drugs (<year>2012</year>) <volume>26</volume>(<issue>5</issue>):<fpage>421</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="doi">10.2165/11631990-000000000-00000</pub-id><pub-id pub-id-type="pmid">22519922</pub-id></mixed-citation>
</ref>
<ref id="B153">
<label>153</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guenther</surname><given-names>PM</given-names></name><name><surname>Casavale</surname><given-names>KO</given-names></name><name><surname>Reedy</surname><given-names>J</given-names></name><name><surname>Kirkpatrick</surname><given-names>SI</given-names></name><name><surname>Hiza</surname><given-names>HA</given-names></name><name><surname>Kuczynski</surname><given-names>KJ</given-names></name><etal></etal></person-group>
<article-title>Update of the Healthy Eating Index: HEI-2010</article-title>. <source/>J Acad Nutr Diet (<year>2013</year>) <volume>113</volume>(<issue>4</issue>):<fpage>569</fpage>–<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1016/j.jand.2012.12.016</pub-id><pub-id pub-id-type="pmid">23415502</pub-id></mixed-citation>
</ref>
<ref id="B154">
<label>154</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akbaraly</surname><given-names>TN</given-names></name><name><surname>Singh-Manoux</surname><given-names>A</given-names></name><name><surname>Tabak</surname><given-names>AG</given-names></name><name><surname>Jokela</surname><given-names>M</given-names></name><name><surname>Virtanen</surname><given-names>M</given-names></name><name><surname>Ferrie</surname><given-names>JE</given-names></name><etal></etal></person-group>
<article-title>Overall diet history and reversibility of the metabolic syndrome over 5 years: the Whitehall II prospective cohort study</article-title>. <source/>Diabetes Care (<year>2010</year>) <volume>33</volume>(<issue>11</issue>):<fpage>2339</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="doi">10.2337/dc09-2200</pub-id><pub-id pub-id-type="pmid">20671094</pub-id></mixed-citation>
</ref>
<ref id="B155">
<label>155</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>PY</given-names></name><name><surname>Huang</surname><given-names>CL</given-names></name><name><surname>Lei</surname><given-names>WS</given-names></name><name><surname>Yang</surname><given-names>SH</given-names></name></person-group>. <article-title>Alternative health eating index and the dietary guidelines from American Diabetes Association both may reduce the risk of cardiovascular disease in type 2 diabetes patients</article-title>. <source/>J Hum Nutr Diet (<year>2016</year>) <volume>29</volume>(<issue>3</issue>):<fpage>363</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="doi">10.1111/jhn.12317</pub-id><pub-id pub-id-type="pmid">26010198</pub-id></mixed-citation>
</ref>
<ref id="B156">
<label>156</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sánchez-Villegas</surname><given-names>A</given-names></name><name><surname>Henríquez-Sánchez</surname><given-names>P</given-names></name><name><surname>Ruiz-Canela</surname><given-names>M</given-names></name><name><surname>Lahortiga</surname><given-names>F</given-names></name><name><surname>Molero</surname><given-names>P</given-names></name><name><surname>Toledo</surname><given-names>E</given-names></name><etal></etal></person-group>
<article-title>A longitudinal analysis of diet quality scores and the risk of incident depression in the SUN Project</article-title>. <source/>BMC Med (<year>2015</year>) <volume>13</volume>:<fpage>197</fpage>.<pub-id pub-id-type="doi">10.1186/s12916-015-0428-y</pub-id><pub-id pub-id-type="pmid">26377327</pub-id></mixed-citation>
</ref>
<ref id="B157">
<label>157</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozawa</surname><given-names>M</given-names></name><name><surname>Shipley</surname><given-names>M</given-names></name><name><surname>Kivimaki</surname><given-names>M</given-names></name><name><surname>Singh-Manoux</surname><given-names>A</given-names></name><name><surname>Brunner</surname><given-names>EJ</given-names></name></person-group>. <article-title>Dietary pattern, inflammation and cognitive decline: the Whitehall II prospective cohort study</article-title>. <source/>Clin Nutr (<year>2016</year>).<pub-id pub-id-type="doi">10.1016/j.clnu.2016.01.013</pub-id><pub-id pub-id-type="pmid">26874911</pub-id></mixed-citation>
</ref>
<ref id="B158">
<label>158</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turnbaugh</surname><given-names>PJ</given-names></name><name><surname>Ley</surname><given-names>RE</given-names></name><name><surname>Mahowald</surname><given-names>MA</given-names></name><name><surname>Magrini</surname><given-names>V</given-names></name><name><surname>Mardis</surname><given-names>ER</given-names></name><name><surname>Gordon</surname><given-names>JI</given-names></name></person-group>
<article-title>An obesity-associated gut microbiome with increased capacity for energy harvest</article-title>. <source/>Nature (<year>2006</year>) <volume>444</volume>:<fpage>1027</fpage>–<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1038/nature05414</pub-id><pub-id pub-id-type="pmid">17183312</pub-id></mixed-citation>
</ref>
<ref id="B159">
<label>159</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turnbaugh</surname><given-names>PJ</given-names></name><name><surname>Hamady</surname><given-names>M</given-names></name><name><surname>Yatsunenko</surname><given-names>T</given-names></name><name><surname>Cantarel</surname><given-names>BL</given-names></name><name><surname>Duncan</surname><given-names>A</given-names></name><name><surname>Ley</surname><given-names>RE</given-names></name><etal></etal></person-group>
<article-title>A core gut microbiome in obese and lean twins</article-title>. <source/>Nature (<year>2009</year>) <volume>457</volume>(<issue>7228</issue>):<fpage>480</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1038/nature07540</pub-id><pub-id pub-id-type="pmid">19043404</pub-id></mixed-citation>
</ref>
<ref id="B160">
<label>160</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>SF</given-names></name><name><surname>Murphy</surname><given-names>EF</given-names></name><name><surname>Nilaweera</surname><given-names>K</given-names></name><name><surname>Ross</surname><given-names>PR</given-names></name><name><surname>Shanahan</surname><given-names>F</given-names></name><name><surname>O’Toole</surname><given-names>PW</given-names></name><etal></etal></person-group>
<article-title>The gut microbiota and its relationship to diet and obesity: new insights</article-title>. <source/>Gut Microbes (<year>2012</year>) <volume>3</volume>(<issue>3</issue>):<fpage>186</fpage>–<lpage>202</lpage>.<pub-id pub-id-type="doi">10.4161/gmic.20168</pub-id><pub-id pub-id-type="pmid">22572830</pub-id></mixed-citation>
</ref>
<ref id="B161">
<label>161</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreno-Indias</surname><given-names>I</given-names></name><name><surname>Cardona</surname><given-names>F</given-names></name><name><surname>Tinahones</surname><given-names>FJ</given-names></name><name><surname>Queipo-Ortuño</surname><given-names>MI</given-names></name></person-group>. <article-title>Impact of the gut microbiota on the development of obesity and type 2 diabetes mellitus</article-title>. <source/>Front Microbiol (<year>2014</year>) <volume>5</volume>:<fpage>190</fpage>.<pub-id pub-id-type="doi">10.3389/fmicb.2014.00190</pub-id><pub-id pub-id-type="pmid">24808896</pub-id></mixed-citation>
</ref>
<ref id="B162">
<label>162</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Santisteban</surname><given-names>MM</given-names></name><name><surname>Rodriguez</surname><given-names>V</given-names></name><name><surname>Li</surname><given-names>E</given-names></name><name><surname>Ahmari</surname><given-names>N</given-names></name><name><surname>Carvajal</surname><given-names>JM</given-names></name><etal></etal></person-group>
<article-title>Gut dysbiosis is linked to hypertension</article-title>. <source/>Hypertension (<year>2015</year>) <volume>65</volume>(<issue>6</issue>):<fpage>1331</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.115.05315</pub-id><pub-id pub-id-type="pmid">25870193</pub-id></mixed-citation>
</ref>
<ref id="B163">
<label>163</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davey</surname><given-names>KJ</given-names></name><name><surname>Cotter</surname><given-names>PD</given-names></name><name><surname>O’Sullivan</surname><given-names>O</given-names></name><name><surname>Crispie</surname><given-names>F</given-names></name><name><surname>Dinan</surname><given-names>TG</given-names></name><name><surname>Cryan</surname><given-names>JF</given-names></name><etal></etal></person-group>
<article-title>Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat</article-title>. <source/>Transl Psychiatry (<year>2013</year>) <volume>3</volume>(<issue>10</issue>):<fpage>e309</fpage>.<pub-id pub-id-type="doi">10.1038/tp.2013.83</pub-id><pub-id pub-id-type="pmid">24084940</pub-id></mixed-citation>
</ref>
<ref id="B164">
<label>164</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>Y-Q</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>S-B</given-names></name><name><surname>Yang</surname><given-names>X-H</given-names></name><name><surname>Cai</surname><given-names>D-B</given-names></name><name><surname>Ng</surname><given-names>CH</given-names></name><etal></etal></person-group>
<article-title>Adjunctive minocycline for schizophrenia: a meta-analysis of randomized controlled trials</article-title>. <source/>Eur Neuropsychopharmacol (<year>2017</year>) <volume>27</volume>(<issue>1</issue>):<fpage>8</fpage>–<lpage>18</lpage>.<pub-id pub-id-type="doi">10.1016/j.euroneuro.2016.11.012</pub-id><pub-id pub-id-type="pmid">27919523</pub-id></mixed-citation>
</ref>
<ref id="B165">
<label>165</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>AP</given-names></name><name><surname>Crowley</surname><given-names>JJ</given-names></name><name><surname>Nonneman</surname><given-names>RJ</given-names></name><name><surname>Quackenbush</surname><given-names>CR</given-names></name><name><surname>Miller</surname><given-names>CN</given-names></name><name><surname>Ryan</surname><given-names>AK</given-names></name><etal></etal></person-group>
<article-title>The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse</article-title>. <source/>PLoS One (<year>2014</year>) <volume>9</volume>(<issue>12</issue>):<fpage>e115225</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0115225</pub-id><pub-id pub-id-type="pmid">25506936</pub-id></mixed-citation>
</ref>
<ref id="B166">
<label>166</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahra</surname><given-names>SM</given-names></name><name><surname>Weidemann</surname><given-names>BJ</given-names></name><name><surname>Castro</surname><given-names>AN</given-names></name><name><surname>Walsh</surname><given-names>JW</given-names></name><name><surname>deLeon</surname><given-names>O</given-names></name><name><surname>Burnett</surname><given-names>CM</given-names></name><etal></etal></person-group>
<article-title>Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure</article-title>. <source/>EBioMedicine (<year>2015</year>) <volume>2</volume>(<issue>11</issue>):<fpage>1725</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="doi">10.1016/j.ebiom.2015.10.018</pub-id><pub-id pub-id-type="pmid">26870798</pub-id></mixed-citation>
</ref>
<ref id="B167">
<label>167</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakraborti</surname><given-names>CK</given-names></name></person-group>. <article-title>New-found link between microbiota and obesity</article-title>. <source/>World J Gastrointest Pathophysiol (<year>2015</year>) <volume>6</volume>(<issue>4</issue>):<fpage>110</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.4291/wjgp.v6.i4.110</pub-id><pub-id pub-id-type="pmid">26600968</pub-id></mixed-citation>
</ref>
<ref id="B168">
<label>168</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simpson</surname><given-names>HL</given-names></name><name><surname>Campbell</surname><given-names>BJ</given-names></name></person-group>. <article-title>Review article: dietary fibre-microbiota interactions</article-title>. <source/>Aliment Pharmacol Ther (<year>2015</year>) <volume>42</volume>(<issue>2</issue>):<fpage>158</fpage>–<lpage>79</lpage>.<pub-id pub-id-type="doi">10.1111/apt.13248</pub-id><pub-id pub-id-type="pmid">26011307</pub-id></mixed-citation>
</ref>
<ref id="B169">
<label>169</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Den Besten</surname><given-names>G</given-names></name><name><surname>van Eunen</surname><given-names>K</given-names></name><name><surname>Groen</surname><given-names>AK</given-names></name><name><surname>Venema</surname><given-names>K</given-names></name><name><surname>Reijngoud</surname><given-names>D-J</given-names></name><name><surname>Bakker</surname><given-names>BM</given-names></name></person-group>. <article-title>The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism</article-title>. <source/>J Lipid Res (<year>2013</year>) <volume>54</volume>(<issue>9</issue>):<fpage>2325</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="doi">10.1194/jlr.R036012</pub-id><pub-id pub-id-type="pmid">23821742</pub-id></mixed-citation>
</ref>
<ref id="B170">
<label>170</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frost</surname><given-names>G</given-names></name><name><surname>Sleeth</surname><given-names>ML</given-names></name><name><surname>Sahuri-Arisoylu</surname><given-names>M</given-names></name><name><surname>Lizarbe</surname><given-names>B</given-names></name><name><surname>Cerdan</surname><given-names>S</given-names></name><name><surname>Brody</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism</article-title>. <source/>Nat Commun (<year>2014</year>) <volume>5</volume>:<fpage>3611</fpage>.<pub-id pub-id-type="doi">10.1038/ncomms4611</pub-id><pub-id pub-id-type="pmid">24781306</pub-id></mixed-citation>
</ref>
<ref id="B171">
<label>171</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacFabe</surname><given-names>DF</given-names></name></person-group>. <article-title>Enteric short-chain fatty acids: microbial messengers of metabolism, mitochondria, and mind: implications in autism spectrum disorders</article-title>. <source/>Microb Ecol Health Dis (<year>2015</year>) <volume>26</volume>:<fpage>28177</fpage>.<pub-id pub-id-type="doi">10.3402/mehd.v26.28177</pub-id><pub-id pub-id-type="pmid">26031685</pub-id></mixed-citation>
</ref>
<ref id="B172">
<label>172</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suyama</surname><given-names>S</given-names></name><name><surname>Maekawa</surname><given-names>F</given-names></name><name><surname>Maejima</surname><given-names>Y</given-names></name><name><surname>Kubota</surname><given-names>N</given-names></name><name><surname>Kadowaki</surname><given-names>T</given-names></name><name><surname>Yada</surname><given-names>T</given-names></name></person-group>. <article-title>Glucose level determines excitatory or inhibitory effects of adiponectin on arcuate POMC neuron activity and feeding</article-title>. <source/>Sci Rep (<year>2016</year>) <volume>6</volume>:<lpage>30796</lpage>.<pub-id pub-id-type="doi">10.1038/srep30796</pub-id><pub-id pub-id-type="pmid">27503800</pub-id></mixed-citation>
</ref>
<ref id="B173">
<label>173</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Yao</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>Z</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><etal></etal></person-group>
<article-title>Adiponectin potentiates the acute effects of leptin in arcuate Pomc neurons</article-title>. <source/>Mol Metab (<year>2016</year>) <volume>5</volume>(<issue>10</issue>):<fpage>882</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1016/j.molmet.2016.08.007</pub-id><pub-id pub-id-type="pmid">27689001</pub-id></mixed-citation>
</ref>
<ref id="B174">
<label>174</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartoli</surname><given-names>F</given-names></name><name><surname>Crocamo</surname><given-names>C</given-names></name><name><surname>Clerici</surname><given-names>M</given-names></name><name><surname>Carrà</surname><given-names>G</given-names></name></person-group>. <article-title>Second-generation antipsychotics and adiponectin levels in schizophrenia: a comparative meta-analysis</article-title>. <source/>Eur Neuropsychopharmacol (<year>2015</year>) <volume>25</volume>(<issue>10</issue>):<fpage>1767</fpage>–<lpage>74</lpage>.<pub-id pub-id-type="doi">10.1016/j.euroneuro.2015.06.011</pub-id><pub-id pub-id-type="pmid">26164075</pub-id></mixed-citation>
</ref>
<ref id="B175">
<label>175</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>YM</given-names></name><name><surname>Chen</surname><given-names>TT</given-names></name><name><surname>Yang</surname><given-names>WS</given-names></name><name><surname>Chi</surname><given-names>YC</given-names></name><name><surname>Lin</surname><given-names>CC</given-names></name><name><surname>Liou</surname><given-names>YJ</given-names></name><etal></etal></person-group>
<article-title>Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study</article-title>. <source/>Schizophr Res (<year>2009</year>) <volume>111</volume>(<issue>1–3</issue>):<fpage>1</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.schres.2009.03.014</pub-id><pub-id pub-id-type="pmid">19409756</pub-id></mixed-citation>
</ref>
<ref id="B176">
<label>176</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadowaki</surname><given-names>T</given-names></name><name><surname>Yamauchi</surname><given-names>T</given-names></name><name><surname>Kubota</surname><given-names>N</given-names></name><name><surname>Hara</surname><given-names>K</given-names></name><name><surname>Ueki</surname><given-names>K</given-names></name><name><surname>Tobe</surname><given-names>K</given-names></name></person-group>. <article-title>Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome</article-title>. <source/>J Clin Invest (<year>2006</year>) <volume>116</volume>(<issue>7</issue>):<fpage>1784</fpage>–<lpage>92</lpage>.<pub-id pub-id-type="doi">10.1172/JCI29126</pub-id><pub-id pub-id-type="pmid">16823476</pub-id></mixed-citation>
</ref>
<ref id="B177">
<label>177</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruce</surname><given-names>CR</given-names></name><name><surname>Mertz</surname><given-names>VA</given-names></name><name><surname>Heigenhauser</surname><given-names>GJ</given-names></name><name><surname>Dyck</surname><given-names>DJ</given-names></name></person-group>. <article-title>The stimulatory effect of globular adiponectin on insulin-stimulated glucose uptake and fatty acid oxidation is impaired in skeletal muscle from obese subjects</article-title>. <source/>Diabetes (<year>2005</year>) <volume>54</volume>(<issue>11</issue>):<fpage>3154</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="doi">10.2337/diabetes.54.11.3154</pub-id><pub-id pub-id-type="pmid">16249439</pub-id></mixed-citation>
</ref>
<ref id="B178">
<label>178</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>FM</given-names></name><name><surname>de Almeida</surname><given-names>JC</given-names></name><name><surname>Feoli</surname><given-names>AM</given-names></name></person-group>. <article-title>Effect of diet on adiponectin levels in blood</article-title>. <source/>Nutr Rev (<year>2011</year>) <volume>69</volume>(<issue>10</issue>):<fpage>599</fpage>–<lpage>612</lpage>.<pub-id pub-id-type="doi">10.1111/j.1753-4887.2011.00414.x</pub-id><pub-id pub-id-type="pmid">21967160</pub-id></mixed-citation>
</ref>
<ref id="B179">
<label>179</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slavin</surname><given-names>J</given-names></name></person-group>. <article-title>Fiber and prebiotics: mechanisms and health benefits</article-title>. <source/>Nutrients (<year>2013</year>) <volume>5</volume>(<issue>4</issue>):<fpage>1417</fpage>–<lpage>35</lpage>.<pub-id pub-id-type="doi">10.3390/nu5041417</pub-id><pub-id pub-id-type="pmid">23609775</pub-id></mixed-citation>
</ref>
<ref id="B180">
<label>180</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henderson</surname><given-names>DC</given-names></name><name><surname>Borba</surname><given-names>CP</given-names></name><name><surname>Daley</surname><given-names>TB</given-names></name><name><surname>Boxill</surname><given-names>R</given-names></name><name><surname>Nguyen</surname><given-names>DD</given-names></name><name><surname>Culhane</surname><given-names>MA</given-names></name><etal></etal></person-group>
<article-title>Dietary intake profile of patients with schizophrenia</article-title>. <source/>Ann Clin Psychiatry (<year>2006</year>) <volume>18</volume>(<issue>2</issue>):<fpage>99</fpage>–<lpage>105</lpage>.<pub-id pub-id-type="doi">10.1080/10401230600614538</pub-id><pub-id pub-id-type="pmid">16754415</pub-id></mixed-citation>
</ref>
<ref id="B181">
<label>181</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutiérrez-Díaz</surname><given-names>I</given-names></name><name><surname>Fernández-Navarro</surname><given-names>T</given-names></name><name><surname>Sánchez</surname><given-names>B</given-names></name><name><surname>Margolles</surname><given-names>A</given-names></name><name><surname>González</surname><given-names>S</given-names></name></person-group>. <article-title>Mediterranean diet and faecal microbiota: a transversal study</article-title>. <source/>Food Funct (<year>2016</year>) <volume>7</volume>(<issue>5</issue>):<fpage>2347</fpage>–<lpage>56</lpage>.<pub-id pub-id-type="doi">10.1039/c6fo00105j</pub-id><pub-id pub-id-type="pmid">27137178</pub-id></mixed-citation>
</ref>
<ref id="B182">
<label>182</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>LC</given-names></name><name><surname>Huang</surname><given-names>KC</given-names></name><name><surname>Wu</surname><given-names>YW</given-names></name><name><surname>Kao</surname><given-names>HL</given-names></name><name><surname>Chen</surname><given-names>CL</given-names></name><name><surname>Lai</surname><given-names>LP</given-names></name><etal></etal></person-group>
<article-title>The clinical implications of blood adiponectin in cardiometabolic disorders</article-title>. <source/>J Formos Med Assoc (<year>2009</year>) <volume>108</volume>(<issue>5</issue>):<fpage>353</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="doi">10.1016/S0929-6646(09)60079-6</pub-id><pub-id pub-id-type="pmid">19443289</pub-id></mixed-citation>
</ref>
<ref id="B183">
<label>183</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papathanasopoulos</surname><given-names>A</given-names></name><name><surname>Camilleri</surname><given-names>M</given-names></name></person-group>. <article-title>Dietary fiber supplements: effects in obesity and metabolic syndrome and relationship to gastrointestinal functions</article-title>. <source/>Gastroenterology (<year>2010</year>) <volume>138</volume>(<issue>1</issue>):<fpage>.e1</fpage>–<lpage>2</lpage>.<pub-id pub-id-type="doi">10.1053/j.gastro.2009.11.045</pub-id><pub-id pub-id-type="pmid">19931537</pub-id></mixed-citation>
</ref>
<ref id="B184">
<label>184</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyon</surname><given-names>MR</given-names></name><name><surname>Kacinik</surname><given-names>V</given-names></name></person-group>. <article-title>Is there a place for dietary fiber supplements in weight management?</article-title>
<source/>Curr Obes Rep (<year>2012</year>) <volume>1</volume>(<issue>2</issue>):<fpage>59</fpage>–<lpage>67</lpage>.<pub-id pub-id-type="doi">10.1007/s13679-012-0016-9</pub-id><pub-id pub-id-type="pmid">22611521</pub-id></mixed-citation>
</ref>
<ref id="B185">
<label>185</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>JB</given-names></name><name><surname>Högger</surname><given-names>P</given-names></name></person-group>. <article-title>Dietary polyphenols and type 2 diabetes: current insights and future perspectives</article-title>. <source/>Curr Med Chem (<year>2015</year>) <volume>22</volume>(<issue>1</issue>):<fpage>23</fpage>–<lpage>38</lpage>.<pub-id pub-id-type="doi">10.2174/0929867321666140706130807</pub-id><pub-id pub-id-type="pmid">25005188</pub-id></mixed-citation>
</ref>
<ref id="B186">
<label>186</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trebatická</surname><given-names>J</given-names></name><name><surname>Ďuračková</surname><given-names>Z</given-names></name></person-group>. <article-title>Psychiatric disorders and polyphenols: can they be helpful in therapy?</article-title>
<source/>Oxid Med Cell Longev (<year>2015</year>) <volume>2015</volume>:<fpage>248529</fpage>.<pub-id pub-id-type="doi">10.1155/2015/248529</pub-id><pub-id pub-id-type="pmid">26180581</pub-id></mixed-citation>
</ref>
<ref id="B187">
<label>187</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dueñas</surname><given-names>M</given-names></name><name><surname>Muñoz-González</surname><given-names>I</given-names></name><name><surname>Cueva</surname><given-names>C</given-names></name><name><surname>Jiménez-Girón</surname><given-names>A</given-names></name><name><surname>Sánchez-Patán</surname><given-names>F</given-names></name><name><surname>Santos-Buelga</surname><given-names>C</given-names></name><etal></etal></person-group>
<article-title>A survey of modulation of gut microbiota by dietary polyphenols</article-title>. <source/>Biomed Res Int (<year>2015</year>) <volume>2015</volume>:<fpage>850902</fpage>.<pub-id pub-id-type="doi">10.1155/2015/850902</pub-id><pub-id pub-id-type="pmid">25793210</pub-id></mixed-citation>
</ref>
<ref id="B188">
<label>188</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catoire</surname><given-names>M</given-names></name><name><surname>Kersten</surname><given-names>S</given-names></name></person-group>. <article-title>The search for exercise factors in humans</article-title>. <source/>FASEB J (<year>2015</year>) <volume>29</volume>(<issue>5</issue>):<fpage>1615</fpage>–<lpage>28</lpage>.<pub-id pub-id-type="doi">10.1096/fj.14-263699</pub-id><pub-id pub-id-type="pmid">25593123</pub-id></mixed-citation>
</ref>
<ref id="B189">
<label>189</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schnyder</surname><given-names>S</given-names></name><name><surname>Handschin</surname><given-names>C</given-names></name></person-group>
<article-title>Skeletal muscle as an endocrine organ: PGC-1α, myokines and exercise</article-title>. <source/>Bone (<year>2015</year>) <volume>80</volume>:<fpage>115</fpage>–<lpage>25</lpage>.<pub-id pub-id-type="doi">10.1016/j.bone.2015.02.008</pub-id><pub-id pub-id-type="pmid">26453501</pub-id></mixed-citation>
</ref>
<ref id="B190">
<label>190</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wueest</surname><given-names>S</given-names></name><name><surname>Item</surname><given-names>F</given-names></name><name><surname>Boyle</surname><given-names>CN</given-names></name><name><surname>Jirkof</surname><given-names>P</given-names></name><name><surname>Cesarovic</surname><given-names>N</given-names></name><name><surname>Ellingsgaard</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Interleukin-6 contributes to early fasting-induced free fatty acid mobilization in mice</article-title>. <source/>Am J Physiol Regul Integr Comp Physiol (<year>2014</year>) <volume>306</volume>(<issue>11</issue>):<fpage>R861</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1152/ajpregu.00533.2013</pub-id><pub-id pub-id-type="pmid">24694381</pub-id></mixed-citation>
</ref>
<ref id="B191">
<label>191</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oropeza</surname><given-names>D</given-names></name><name><surname>Jouvet</surname><given-names>N</given-names></name><name><surname>Bouyakdan</surname><given-names>K</given-names></name><name><surname>Perron</surname><given-names>G</given-names></name><name><surname>Ringuette</surname><given-names>LJ</given-names></name><name><surname>Philipson</surname><given-names>LH</given-names></name><etal></etal></person-group>
<article-title>PGC-1 coactivators in β-cells regulate lipid metabolism and are essential for insulin secretion coupled to fatty acids</article-title>. <source/>Mol Metab (<year>2015</year>) <volume>4</volume>(<issue>11</issue>):<fpage>811</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1016/j.molmet.2015.08.001</pub-id><pub-id pub-id-type="pmid">26629405</pub-id></mixed-citation>
</ref>
<ref id="B192">
<label>192</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Leusden</surname><given-names>JWR</given-names></name><name><surname>Sellaro</surname><given-names>R</given-names></name><name><surname>Colzato</surname><given-names>LS</given-names></name></person-group>
<article-title>Transcutaneous vagal nerve stimulation (tVNS): a new neuromodulation tool in healthy humans?</article-title>
<source/>Front Psychol (<year>2015</year>) <volume>6</volume>:<fpage>102</fpage><pub-id pub-id-type="doi">10.3389/fpsyg.2015.00102</pub-id><pub-id pub-id-type="pmid">25713547</pub-id></mixed-citation>
</ref>
<ref id="B193">
<label>193</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanaley</surname><given-names>JA</given-names></name><name><surname>Goulopoulou</surname><given-names>S</given-names></name><name><surname>Franklin</surname><given-names>R</given-names></name><name><surname>Baynard</surname><given-names>T</given-names></name><name><surname>Carhart</surname><given-names>RL</given-names><suffix>Jr</suffix></name><name><surname>Weinstock</surname><given-names>RS</given-names></name><etal></etal></person-group>
<article-title>Exercise training improves hemodynamic recovery to isometric exercise in obese men with type 2 diabetes but not in obese women</article-title>. <source/>Metabolism (<year>2012</year>) <volume>61</volume>(<issue>12</issue>):<fpage>1739</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="doi">10.1016/j.metabol.2012.07.014</pub-id><pub-id pub-id-type="pmid">22902004</pub-id></mixed-citation>
</ref>
<ref id="B194">
<label>194</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rojhani-Shirazi</surname><given-names>Z</given-names></name><name><surname>Barzintaj</surname><given-names>F</given-names></name><name><surname>Salimifard</surname><given-names>MR</given-names></name></person-group>
<article-title>Comparison the effects of two types of therapeutic exercises Frenkele vs. Swiss ball on the clinical balance measures in patients with type II diabetic neuropathy</article-title>. <source/>Diabetes Metab Syndr (<year>2016</year>).<pub-id pub-id-type="doi">10.1016/j.dsx.2016.08.020</pub-id></mixed-citation>
</ref>
<ref id="B195">
<label>195</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sá-Caputo Dda</surname><given-names>C</given-names></name><name><surname>Ronikeili-Costa</surname><given-names>P</given-names></name><name><surname>Carvalho-Lima</surname><given-names>RP</given-names></name><name><surname>Bernardo</surname><given-names>LC</given-names></name><name><surname>Bravo-Monteiro</surname><given-names>MO</given-names></name><name><surname>Costa</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title>Whole body vibration exercises and the improvement of the flexibility in patient with metabolic syndrome</article-title>. <source/>Rehabil Res Pract (<year>2014</year>) <volume>2014</volume>:<fpage>628518</fpage>.<pub-id pub-id-type="doi">10.1155/2014/628518</pub-id><pub-id pub-id-type="pmid">25276434</pub-id></mixed-citation>
</ref>
<ref id="B196">
<label>196</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerrillo-Urbina</surname><given-names>AJ</given-names></name><name><surname>García-Hermoso</surname><given-names>A</given-names></name><name><surname>Sánchez-López</surname><given-names>M</given-names></name><name><surname>Pardo-Guijarro</surname><given-names>MJ</given-names></name><name><surname>Santos Gómez</surname><given-names>JL</given-names></name><name><surname>Martínez-Vizcaíno</surname><given-names>V</given-names></name></person-group>. <article-title>The effects of physical exercise in children with attention deficit hyperactivity disorder: a systematic review and meta-analysis of randomized control trials</article-title>. <source/>Child Care Health Dev (<year>2015</year>) <volume>41</volume>(<issue>6</issue>):<fpage>779</fpage>–<lpage>88</lpage>.<pub-id pub-id-type="doi">10.1111/cch.12255</pub-id><pub-id pub-id-type="pmid">25988743</pub-id></mixed-citation>
</ref>
<ref id="B197">
<label>197</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malchow</surname><given-names>B</given-names></name><name><surname>Reich-Erkelenz</surname><given-names>D</given-names></name><name><surname>Oertel-Knöchel</surname><given-names>V</given-names></name><name><surname>Keller</surname><given-names>K</given-names></name><name><surname>Hasan</surname><given-names>A</given-names></name><name><surname>Schmitt</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>The effects of physical exercise in schizophrenia and affective disorders</article-title>. <source/>Eur Arch Psychiatry Clin Neurosci (<year>2013</year>) <volume>263</volume>(<issue>6</issue>):<fpage>451</fpage>–<lpage>67</lpage>.<pub-id pub-id-type="doi">10.1007/s00406-013-0423-2</pub-id><pub-id pub-id-type="pmid">23873090</pub-id></mixed-citation>
</ref>
<ref id="B198">
<label>198</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>MA</given-names></name><name><surname>Lynch</surname><given-names>WJ</given-names></name></person-group>
<article-title>Exercise as a potential treatment for drug abuse: evidence from preclinical studies</article-title>. <source/>Front Psychiatry (<year>2011</year>) <volume>2</volume>:<fpage>82</fpage><pub-id pub-id-type="doi">10.3389/fpsyt.2011.00082</pub-id><pub-id pub-id-type="pmid">22347866</pub-id></mixed-citation>
</ref>
<ref id="B199">
<label>199</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vidoni</surname><given-names>ED</given-names></name><name><surname>Van Sciver</surname><given-names>A</given-names></name><name><surname>Johnson</surname><given-names>DK</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Honea</surname><given-names>R</given-names></name><name><surname>Haines</surname><given-names>B</given-names></name><etal></etal></person-group>
<article-title>A community-based approach to trials of aerobic exercise in aging and Alzheimer’s disease</article-title>. <source/>Contemp Clin Trials (<year>2012</year>) <volume>33</volume>(<issue>6</issue>):<fpage>1105</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="doi">10.1016/j.cct.2012.08.002</pub-id><pub-id pub-id-type="pmid">22903151</pub-id></mixed-citation>
</ref>
<ref id="B200">
<label>200</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeFronzo</surname><given-names>RA</given-names></name><name><surname>Tripathy</surname><given-names>D</given-names></name></person-group>
<article-title>Skeletal muscle insulin resistance is the primary defect in type 2 diabetes</article-title>. <source/>Diabetes Care (<year>2009</year>) <volume>32</volume>(<issue>Suppl 2</issue>):<fpage>S157</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="doi">10.2337/dc09-S302</pub-id><pub-id pub-id-type="pmid">19875544</pub-id></mixed-citation>
</ref>
<ref id="B201">
<label>201</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banks</surname><given-names>WA</given-names></name><name><surname>Owen</surname><given-names>JB</given-names></name><name><surname>Erickson</surname><given-names>MA</given-names></name></person-group>. <article-title>Insulin in the brain: there and back again</article-title>. <source/>Pharmacol Ther (<year>2012</year>) <volume>136</volume>(<issue>1</issue>):<fpage>82</fpage>–<lpage>93</lpage>.<pub-id pub-id-type="doi">10.1016/j.pharmthera.2012.07.006</pub-id><pub-id pub-id-type="pmid">22820012</pub-id></mixed-citation>
</ref>
<ref id="B202">
<label>202</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>SN</given-names></name></person-group>. <article-title>The effect of raising and lowering tryptophan levels on human mood and social behaviour</article-title>. <source/>Philos Trans R Soc Lond B Biol Sci (<year>2013</year>) <volume>368</volume>(<issue>1615</issue>):<fpage>20110375</fpage>.<pub-id pub-id-type="doi">10.1098/rstb.2011.0375</pub-id><pub-id pub-id-type="pmid">23440461</pub-id></mixed-citation>
</ref>
<ref id="B203">
<label>203</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mosienko</surname><given-names>V</given-names></name><name><surname>Bert</surname><given-names>B</given-names></name><name><surname>Beis</surname><given-names>D</given-names></name><name><surname>Matthes</surname><given-names>S</given-names></name><name><surname>Fink</surname><given-names>H</given-names></name><name><surname>Bader</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Exaggerated aggression and decreased anxiety in mice deficient in brain serotonin</article-title>. <source/>Transl Psychiatry (<year>2012</year>) <volume>2</volume>(<issue>5</issue>):<fpage>e122</fpage>.<pub-id pub-id-type="doi">10.1038/tp.2012.44</pub-id><pub-id pub-id-type="pmid">22832966</pub-id></mixed-citation>
</ref>
<ref id="B204">
<label>204</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marsh</surname><given-names>DM</given-names></name><name><surname>Dougherty</surname><given-names>DM</given-names></name><name><surname>Moeller</surname><given-names>FG</given-names></name><name><surname>Swann</surname><given-names>AC</given-names></name><name><surname>Spiga</surname><given-names>R</given-names></name></person-group>. <article-title>Laboratory-measured aggressive behavior of women: acute tryptophan depletion and augmentation</article-title>. <source/>Neuropsychopharmacology (<year>2002</year>) <volume>26</volume>(<issue>5</issue>):<fpage>660</fpage>–<lpage>71</lpage>.<pub-id pub-id-type="doi">10.1016/S0893-133X(01)00369-4</pub-id><pub-id pub-id-type="pmid">11927191</pub-id></mixed-citation>
</ref>
<ref id="B205">
<label>205</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myint</surname><given-names>AM</given-names></name></person-group>. <article-title>Kynurenines: from the perspective of major psychiatric disorders</article-title>. <source/>FEBS J (<year>2012</year>) <volume>279</volume>(<issue>8</issue>):<fpage>1375</fpage>–<lpage>85</lpage>.<pub-id pub-id-type="doi">10.1111/j.1742-4658.2012.08551.x</pub-id><pub-id pub-id-type="pmid">22404766</pub-id></mixed-citation>
</ref>
<ref id="B206">
<label>206</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beggiato</surname><given-names>S</given-names></name><name><surname>Antonelli</surname><given-names>T</given-names></name><name><surname>Tomasini</surname><given-names>MC</given-names></name><name><surname>Tanganelli</surname><given-names>S</given-names></name><name><surname>Fuxe</surname><given-names>K</given-names></name><name><surname>Schwarcz</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title>Kynurenic acid, by targeting α7 nicotinic acetylcholine receptors, modulates extracellular GABA levels in the rat striatum in vivo</article-title>. <source/>Eur J Neurosci (<year>2013</year>) <volume>37</volume>(<issue>9</issue>):<fpage>1470</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1111/ejn.12160</pub-id><pub-id pub-id-type="pmid">23442092</pub-id></mixed-citation>
</ref>
<ref id="B207">
<label>207</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mudry</surname><given-names>JM</given-names></name><name><surname>Alm</surname><given-names>PS</given-names></name><name><surname>Erhardt</surname><given-names>S</given-names></name><name><surname>Goiny</surname><given-names>M</given-names></name><name><surname>Fritz</surname><given-names>T</given-names></name><name><surname>Caidahl</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>Direct effects of exercise on kynurenine metabolism in people with normal glucose tolerance or type 2 diabetes</article-title>. <source/>Diabetes Metab Res Rev (<year>2016</year>) <volume>32</volume>(<issue>7</issue>):<fpage>754</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1002/dmrr.2798</pub-id><pub-id pub-id-type="pmid">26946084</pub-id></mixed-citation>
</ref>
<ref id="B208">
<label>208</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olsson</surname><given-names>SK</given-names></name><name><surname>Samuelsson</surname><given-names>M</given-names></name><name><surname>Saetre</surname><given-names>P</given-names></name><name><surname>Lindström</surname><given-names>L</given-names></name><name><surname>Jönsson</surname><given-names>EG</given-names></name><name><surname>Nordin</surname><given-names>C</given-names></name><etal></etal></person-group>
<article-title>Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder</article-title>. <source/>J Psychiatry Neurosci (<year>2010</year>) <volume>35</volume>(<issue>3</issue>):<fpage>195</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1503/jpn.090180</pub-id><pub-id pub-id-type="pmid">20420770</pub-id></mixed-citation>
</ref>
<ref id="B209">
<label>209</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>HS</given-names></name><name><surname>Baek</surname><given-names>DJ</given-names></name><name><surname>Baek</surname><given-names>SS</given-names></name></person-group>. <article-title>Effect of exercise on hyperactivity, impulsivity and dopamine D2 receptor expression in the substantia nigra and striatum of spontaneous hypertensive rats</article-title>. <source/>J Exerc Nutrition Biochem (<year>2014</year>) <volume>18</volume>(<issue>4</issue>):<fpage>379</fpage>–<lpage>84</lpage>.<pub-id pub-id-type="doi">10.5717/jenb.2014.18.4.379</pub-id><pub-id pub-id-type="pmid">25671205</pub-id></mixed-citation>
</ref>
<ref id="B210">
<label>210</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herculano-Houzel</surname><given-names>S</given-names></name></person-group>. <article-title>Scaling of brain metabolism with a fixed energy budget per neuron: implications for neuronal activity, plasticity and evolution</article-title>. <source/>PLoS One (<year>2011</year>) <volume>6</volume>(<issue>3</issue>):<fpage>e17514</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0017514</pub-id><pub-id pub-id-type="pmid">21390261</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>